Methods of using alkynylbenzenesulfonamide in combination therapy for cancer treatment

By combining specific benzylsulfonamide thiazole compounds with chemotherapy, targeted therapy, and immunotherapy, an ICD response is triggered, which solves the problem that existing treatments are ineffective against non-immunogenic tumors, achieving more efficient tumor suppression and prolonged survival, while reducing toxicity.

CN123124975APending Publication Date: 2026-11-17BAIBO THERAPEUTICS INC +3
View PDF 25 Cites 0 Cited by

Patent Information

Application Number
CN202580027299.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-19
Filing Date
2025-04-18
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing cancer treatments such as chemotherapy, targeted therapy, and immunotherapy have limited effectiveness in many cases, especially against non-immunogenic tumors, and suffer from serious side effects and drug resistance problems. New anticancer therapies are needed to enhance treatment efficacy and reduce toxicity.

Method used

By using specific benzylsulfonamide thiazole compounds (such as BPR001-615) in combination with chemotherapy, targeted therapy and immunotherapy, the anti-cancer effect is enhanced by triggering immune cell death (ICD) response, releasing calreticulin, HMGB1 and ATP.

Benefits of technology

It significantly enhances the anti-cancer effects of chemotherapy, targeted therapy, and immunotherapy, especially in tumors overexpressing GRP78, providing highly effective tumor growth inhibition and prolonging patient survival, while reducing toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This disclosure relates to the use of specific benzylsulfonamide thiazole compounds in combination with anticancer therapies for the treatment of cancer in patients in need. Using various cancer cell models, the inventors have demonstrated that combination therapy with specific benzylsulfonamide thiazole compounds and anticancer therapies (such as immunotherapies, chemotherapeutic agents, or targeted therapies) allows for the specific triggering of immune cell death markers, thereby enhancing the efficacy of each compound used alone.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to novel cancer therapies. In particular, this disclosure relates to the use of anticancer therapies in combination with benzylsulfonamide thiazole compounds for cancer treatment. Background Technology

[0002] Cancer encompasses a broad class of diseases characterized by uncontrolled cell growth and division. More than 200 forms of cancer are known to collectively impose a significant social burden on the body in terms of lost lives, reduced quality of life, increased healthcare costs, and decreased productivity. Significant progress has been made in the diagnosis, screening, and treatment of cancer over the past decade. However, cancer remains a leading cause of death globally: nearly 10 million people died in 2022 (Global Cancer Observatory: Cancer Today).

[0003] Many types of cancer treatments have been developed and put into use, such as chemotherapy, radiotherapy and immunotherapy.

[0004] Chemotherapy is often part of first-line cancer treatment. While it has shown good efficacy in a wide range of cancers, it is also accompanied by a variety of adverse reactions that can severely impact patients' quality of life, as well as drug resistance mechanisms that affect treatment efficacy. Close management of the dosage and regimen used is crucial for optimizing remission opportunities and maintaining patient health.

[0005] Targeted therapies developed to specifically target genes and molecules directly involved in carcinogenesis and tumor growth have also proven extremely useful. These therapies are a form of personalized medicine, and unlike traditional chemotherapy, they do not "simply" target any rapidly dividing cells. Therefore, targeted therapies are considered to be better tolerated by patients. Unfortunately, these therapies are only suitable for a small percentage of patients, the identification of appropriate molecular targets is still ongoing, and the development of corresponding drugs requires considerable time.

[0006] Immunotherapy has become a recognized and well-established alternative treatment for cancer. It encompasses several different therapies, all based on stimulating a patient's immune system to recognize and attack their disease. Immunotherapy using immune checkpoint modulators has revolutionized the field of oncology (Robert, C. Nat Commun 11, 3801, 2020). Research on the conceptual origins of this type of treatment earned James P. Allison and Tasuku Honjo the 2018 Nobel Prize in Medicine. Immune checkpoints are a large number of inhibitory pathways inherent in the immune system, crucial for maintaining self-tolerance and regulating the duration and intensity of physiological immune responses in peripheral tissues to minimize collateral tissue damage caused by the immune response. When checkpoints bind to their ligands, they send a "shutdown" signal to T cells, thereby suppressing / signally weakening the immune response. It is now clear that tumors utilize certain immune checkpoint pathways to evade the immune response. Immune checkpoint inhibitors (ICIs) prevent the "shutdown" signal from being sent by blocking the binding of checkpoints to their ligands. These compounds have shown significant clinical efficacy and offer great hope for the cure of some refractory tumors. Unfortunately, not all tumors respond to immune checkpoint inhibitors. In some cases, even after the inhibitory signals sent by immune checkpoints are shut down, the immune system still cannot detect and attack the tumor. Some tumors are indeed non-immunogenic, meaning they cannot be detected by immune cells. The immunogenicity of a tumor depends on its antigenicity and a variety of other immunomodulatory factors produced by tumor cells or host cells in the tumor microenvironment. Therefore, non-immunogenic tumors cannot trigger an immune response, regardless of the presence or absence of inhibitory signals sent to immune cells. Non-immunogenic tumors are generally associated with poor prognosis and are largely unresponsive to most treatment strategies.

[0007] Therefore, there is an urgent need for novel anticancer therapies and the identification of new molecules that can enhance the effects of known anticancer treatments. Summary of the Invention

[0008] This invention is defined by the claims.

[0009] The inventors have demonstrated that a very specific group of benzylsulfonamide thiazole compounds can significantly enhance the efficacy of anticancer therapies, including chemotherapy, targeted therapy, and immunotherapy. These very specific compounds, in particular, possess remarkable pharmacokinetic characteristics, allowing for high efficacy and reduced toxicity. They allow for the triggering of potent immune cell death (ICD) responses, including calreticulin cell surface exposure, HMGB1 and AnnexinA1 release, and extracellular ATP release in various cancer cell lines, making them ideal candidates for combination with other anticancer therapies, such as immunotherapy. The inventors have demonstrated that the compounds according to the invention exhibit synergistic effects with various anticancer therapies in a variety of cancer cell lines.

[0010] Therefore, this disclosure relates to the combination of anticancer therapy with a compound of formula (I): [Formula I]: in R1 represents H, methyl, phenyl, or acetyl; R2 represents H, or C2-C 10 Alkyl, cycloalkyl, or hydroxyalkyl; and The alkynyl chain connected to R2 is attached to the benzene ring at the 3 or 4 position. Used to treat cancer in patients who need it.

[0011] Specifically, the compound of formula (I) is the same as the compound of formula (II): [Formula II]: Attached Figure Description

[0012] Figure 1 [ Figure 1 Effects of BPR001-615 (PB615): (A) CHOP-mediated endoplasmic reticulum stress pathway-induced cancer cell death, (B) CHOP-mediated apoptosis and autophagy, (C) Calcium reticulin cell surface exposure in mouse colon cancer cell lines and human melanoma cell lines.

[0013] Figure 2 [ Figure 2 Effects of BPR001-615: (A) release of HMGB1 and Annexin A1, and (B) release of extracellular ATP in human melanoma and osteosarcoma cell lines.

[0014] Figure 3 [ Figure 3 BPR001-615 synergistically induced cancer cell death in gastric cancer cell lines (compared to cancer cell survival with DMSO). WST-1 cell proliferation assay showed cell survival after combined treatment with BPR001-615 and chemotherapy. Two-factor ANOVA test was used. p<0.05, p<0.01, p<0.005, SN-38: irinotecan metabolite SN38, Oxa: oxaliplatin.

[0015] Figure 4 [ Figure 4 Effects of BPR001-615 combined with trastuzumab on the growth of NCI-N87 tumor model in PBMC humanized NXG mice.

[0016] Figure 5 [ Figure 5 The effect of BPR001-615 and trastuzumab on GRP78 concentration on NCI-N87 tumors.

[0017] Figure 6 [ Figure 6 ] Figure 6 A: The effects of BPR001-615 and trastuzumab on immune cell infiltration. Figure 6 B: Effects of BPR001-615 and trastuzumab on NK and Treg cell infiltration.

[0018] Figure 7 [ Figure 7 Synergistic effect of BPR001-615 and SN38 on cell death induction in the CT26 cancer cell line. WST-1 cell proliferation assay and cell survival rate after combined treatment with BPR001-615 and chemotherapy. Two-factor ANOVA test. p<0.05, p<0.01, p<0.005, p<0.0001.

[0019] Figure 8 [ Figure 8 Survival curves after 49 days of treatment with BPR001-615 alone and in combination with α-PD1. mpk: mg / kg; Significant differences in survival between groups were noted. Mice were sacrificed when the tumor volume reached a predetermined size.

[0020] Figure 9 [ Figure 9 Comparable effects of combining two different compounds of formula (I) in cell lines. Figure A9: BPR001-615 and PB673 in ovarian cell lines (OVCAR.3) after 48 hours of cisplatin. Figure 9 B: In the gastric cancer cell line (KatoIII), BPR001-615 and PB673 were combined with irinotecan metabolite SN-38 for 48 hours.

[0021] Figure 10 [ Figure 10 The superior efficacy of BPR001-615 compared to HA15 in combination with different chemotherapy regimens in cell lines. Figure 10 A: BPR001-615 vs HA15 and cisplatin in ovarian cell line (OVCAR.3) 48 hours. Figure 10 B: BPR001-615 vs HA15 and irinotecan metabolite SN-38 in the gastric cancer cell line (KatoIII) 48 hours. Figure 10 C: BPR001-615 vs HA15 and docetaxel in the gastric cancer cell line (KatoIII) 48 hours.

[0022] Figure 11 [ Figure 11 Tumor size evolution of NCI-N87 in PBMC humanized NXG female mice treated with BPR001-615 and trastuzumab as single agents. Left panel: Two-way ANOVA test was used for statistical analysis. Right panel: % tumor growth inhibition compared to solvent treatment on day 1. GRP78 (BiP) overexpression was observed in various cancer cell lines, with NCI-N87 highlighted (Western blot analysis). Detailed Implementation

[0023] Over the past two decades, preclinical and clinical research has redefined the mechanisms of action of some chemotherapeutic drugs, enabling them to activate the immune system to fight cancer when cell death is sensed by immune cells. This immunogenic cell death (ICD) activates antigen-presenting cells (APCs) and T cells to induce immune-mediated tumor clearance. One of the key requirements for achieving this effect is the externalization of damage-associated molecular patterns (DAMPs), which are molecules that increase the visibility of cancer cells to the immune system during ICD, resulting in the release or exposure of cancer cells (Cifric et al.). Antioxidants and Redox Signaling (2024)).

[0024] Immunogenic cell death (ICD) is a unique cell death response pattern that can trigger durable anti-tumor immunity by inducing damage-associated molecular pattern (DAMP) signals such as surface exposure of calreticulin (CRT), ATP release, and HMGB1 secretion. In cancer cells, the immunostimulatory signals released during ICD lead to enhanced phagocytosis of cancer cells by dendritic cells (DCs), the most efficient antigen-presenting cells in the immune system. Cancer-specific antigens are then presented by DCs to relevant T cells, resulting in activation of a global anti-cancer immune response.

[0025] Using various cancer cell line models and in vivo models, the inventors have demonstrated that specific benzylamide thiazole compounds of formula (I) can significantly enhance the efficacy of anticancer therapies (including chemotherapy, targeted therapy, and immunotherapy) by triggering ICD biomarkers that do not trigger or are insufficient to trigger ICD biomarkers leading to DAMP signaling. They possess strong anticancer properties and target GRP78. Surprisingly, the effects obtained when these compounds are combined with anticancer therapies are significantly higher than the effects of using each therapy alone.

[0026] The inventors further demonstrated that this combination therapy, particularly in tumors overexpressing GRP78, triggered significant cytotoxic effects, tumor growth inhibition, and overall patient survival.

[0027] The combination therapy delivered CHOP-mediated cytotoxic effects on cancer cells induced by endoplasmic reticulum (ER) stress, which were significantly higher than those achieved by using each treatment alone.

[0028] Specific compounds of formula (I) exhibit cytotoxic effects on cancer cell lines and are accompanied by ICD properties, triggering three ICD markers in a dose-responsive manner: - Calcium reticulin exposure; - ATP release; and - HMGB1 release.

[0029] These compounds possess two complementary and concomitant effects mediated by GRP78 inhibition and strong ER stress induction, triggering three synergistic antitumor effects: CHOP-mediated apoptosis and autophagy, accompanied by ICD-mediated cell death and tumor destruction, thereby enhancing the efficacy of chemotherapy, targeted therapy, radiotherapy, and immunotherapy.

[0030] Therefore, this invention represents a highly promising cancer treatment therapy.

[0031] Furthermore, the inventors have demonstrated that the compound of formula (I) has an effect at least comparable to well-known standard care, even in tumors with low GRP78 (as defined below).

[0032] Therefore, in a first aspect, this disclosure relates to the combination of anticancer therapy with a compound of formula (I): [Formula I]: in R1 represents H, methyl, phenyl, or acetyl; R2 represents H, or C2-C 10 Alkyl, cycloalkyl, or hydroxyalkyl; and The alkynyl chain connected to R2 is attached to the benzene ring at the 3 or 4 position. Its use in treating cancer in patients in need.

[0033] As used herein, the terms "combination," "co-administration," "conjunctive administration," or "accompaniment administration" preferably refer to the combined administration of at least two therapeutic agents, wherein a first agent (typically a compound of formula (I)) and a second agent are administered simultaneously or separately at time intervals in the same subject in need, where these time intervals allow the combined components to exhibit cooperative or synergistic effects in treating a disease, such as cancer. This does not mean that the therapeutic agents must be administered simultaneously and / or formulated for co-delivery, although such delivery methods are also within the scope described herein. Compounds of formula (I) may be administered simultaneously, before, or after one or more other additional therapies or therapeutic agents. These terms also cover treatment regimens in which the therapeutic agents are not necessarily administered via the same route of administration.

[0034] The term "C2-C" 10 Alkyl refers to a straight-chain or branched saturated hydrocarbon chain containing 2-10 carbon atoms, either monovalent, divalent, or trivalent, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-butylmethyl, n-pentyl, n-hexyl, n-heptyl, or n-octyl.

[0035] The term "cycloalkyl" refers to saturated or unsaturated monocyclic or polycyclic systems containing 3 to 12 carbon atoms, such as fused or bridged bicyclic systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, decahydronaphthyl, or norbornyl.

[0036] The “joint” use under this disclosure covers: - An anticancer treatment / agent for cancer treatment, wherein the anticancer agent is used in combination with a compound of formula (I) as defined above; and - Compounds of formula (I) as defined above, such as BPR001-615, are used for cancer treatment, wherein the compound is used in combination with an anticancer agent.

[0037] The term "joint" use under this disclosure also covers "kit of parts," including: - Anticancer agents; and - Compounds of formula (I) as defined above, Its use in cancer treatment.

[0038] The term "kit kit" in this document refers to a combination formulation in which the active ingredients are used in physically separated form for combined treatment by simultaneous or sequential administration to a patient. Therefore, according to this disclosure, anticancer agents and compounds of formula (I) are administered to a patient individually, simultaneously, separately, or sequentially in any order for cancer treatment.

[0039] According to a further implementation, this disclosure also relates to the reagent kit itself, specifically a reagent kit comprising the following: - Anticancer agents; and - Compounds of formula (I) as defined above, such as BPR001-615.

[0040] Anticancer treatment / dose According to this disclosure, anticancer treatment is any anticancer agent selected from chemotherapy, targeted therapy, immunotherapy, and combinations thereof.

[0041] "Chemotherapy," "chemotherapeutic drugs," and "chemotherapeutic agents" refer to chemical compounds that effectively inhibit tumor growth. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, probenecid, and piperazine; aziridines such as benzodopa, carboquinone, methotrexate, and ursodepipe; ethyleneimine and methylmelamine derivatives including hexamethylmelamine, triethylmelamine, triethylphosphamide, triethylthiophosphamide, and trimethylmelamine; acetylginines (especially blatazine and blatazineone); camptothecin derivatives (including irinotecan and topotecan); bryophytes; carlisstatin; CC-1065 (including its synthetic analogues adolexin, carzelin, and bizelin); cryptophytes (especially cryptophyte 1 and cryptophyte 2). Alginate 8); Dolastamine; Ducamycin (including synthetic analogs KW-2189 and CBI-TMI); Elemisin; Sea sucrose; Salcorditin; Sponge statin; Nitrogen mustards such as chlorambucil, naphthylambucil, chlorphosphamide, estradiol, ifosfamide, nitrogen mustard, nitrogen mustard hydrochloride oxide, melphalan, neoempichine, estradiol, prednimustine, trazophos, uracil mustard; Nitrosoureas such as carmustine, chloramphenicol, formustine, lomustine, nimustine, ramustine; Antibiotics such as enediyne antibiotics (e.g., calimoxycin, especially calimoxycin γ1 and calimoxycin ω, see Agnew Chem Intl. Ed. Engl.).33:183-186 (1994); danendomycin, including danendomycin A; esperamycin; and new carcinogen chromophores and related chromogens (enediyne antibiotic chromophores), aclarubicin, actinomycin, anthramycin, diazoserine, bleomycin, actinomycin C, carabixin, carniycin, carcinogen, chromomycin, actinomycin D, daunorubicin, detoxin, 6-diazo-5-oxo-L-leucine, doxorubicin (including morpholino-dxorubicin, cyanomorpholino-dxorubicin, 2-pyrrololino-dxorubicin and deoxydxorubicin), epirubicin, isorubicin, idarubicin, Macelromycin, mitomycin, mycophenolic acid, nogalamycin, orivomycin, pepromycin, pofibromycin, puromycin, quinacrine, rhodopsin, streptozotocin, streptozotocin, tuberculin, ubenmex, fentostatin, zorobacterium; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as dinotrexate, methotrexate, pteroxate, trimethoprim; purine analogs such as fludarabine, 6-mercaptopurine, thiopurine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmoflurane, cytarabine, dideoxyuridine, deoxyfluoridate. Uric acid, enoxabin, fluorouridine; androgens such as calcitestosterone, drotahistamine propionate, epithranolol, meandranone, testrolide; antiadrenergic drugs such as aminoglutethimide, mitotane, tralostertan; folic acid supplements such as folinic acid; acetoglucuronolactone; aldehyde phosphoramide glycoside; aminolevulinic acid; acridine; bistrabsil; bisperazine; edatrazine; dimethicone; diazinon; efornithine; eliprotinine acetate; epothilone; etoradin; gallium nitrate; hydroxyurea; lentinan; lonidamine; mettansine derivatives such as mettansine and anthraquinone; mittocucurbitone; mittoantrone; moparinol; nitroacin; [unclear text - possibly a typo, should be removed] Stastatin; Finasteride; Pirarubicin; Podophyllin; 2-Ethylhydrazine; Procarbazine; PSK®; Razosen; Rhizomycin; Cizonan; Spirogeron; Alternaria ketoacid; Triaconazole; 2,2',2"-Trichlorotriethylamine; Trichothecenes (especially T-2 toxin, Verrucosporin A, Bacitracin A, and Serpentine); Urethroids; Vinpocetine; Dacarbazine; Mannitol; Mitotrobromide; Mitoprol; Piperabromide; Garcitocin; Cytarabine ("Ara-C"); Cyclophosphamide; Thiotepa; Taxanes, such as paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.).Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, carboplatin, oxaliplatin; vincristine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; vinflunine; novatron; teniposide; daunorubicin; aminopterin; capecitabine; ibandronate sodium; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids, or derivatives of any of the above. This definition also includes antihormonal agents that regulate or inhibit the effects of hormones on tumors, such as antiestrogens, including, for example, tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trivoxifen, kaxifen, LY117018, onanasone, and toremifene (Fareston); and antiandrogens, such as flutamide, nilutel, bicalutamide, leuprorelin, and goserelin; and pharmaceutically acceptable salts, acids, or derivatives of any of the foregoing.

[0042] According to a preferred embodiment, the chemotherapeutic agents used in the context of this disclosure are selected from doxorubicin, toxoids such as paclitaxel and docetaxel, gemcitabine, antimetabolites such as methotrexate and 5-fluorouracil (5-FU), platinum analogs such as cisplatin and oxaliplatin, and camptothecins such as irinotecan and topotecan.

[0043] "Targeted therapy" refers to agents that block cancer cell growth by interfering with specific target molecules required for carcinogenesis and tumor growth. Most targeted therapies are small molecule drugs or monoclonal antibodies. It is worth noting that some targeted therapies can be classified as immunotherapies and / or chemotherapy agents. Examples of targeted therapies include bortezomib, Braf inhibitors such as vemurafenib and dabrafenib, cobitinib, imatinib, gefitinib, erlotinib, sorafenib, sunitinib, dasatinib, lapatinib, nilotinib, tamoxifen, Janus kinase inhibitors such as tofacitinib, ALK inhibitors such as crizotinib, Bcl-2 inhibitors such as venetoclax, ombatac, navitocx, and gossypol, PARP inhibitors such as olaparib, rucaparib, niraparib, and talaparib, and PI3K inhibitors. Pharmaceutical formulations such as perifolliculin, apatinib, zotalorelin, doxorubicin, MEK inhibitors such as trametinib, CDK inhibitors, Hsp90 inhibitors, Hedgehog pathway inhibitors such as vemodega and sondega, salinomycin, VAL-083, Vintafolide, tanciolimus, everolimus, vemurafenib, trametinib, dabrafenib, and monoclonal antibodies, including pembrolizumab, rituximab, alemtuzumab, cetuximab, panitumumab, bevacizumab, and ipilimumab.

[0044] According to a specific implementation scheme, the targeted therapy used in this disclosure is selected from bortezomib, vemurafenib, and cobitinib.

[0045] "Immunotherapy," "immunotherapy drugs," or "immunotherapy agents" refer to compounds, compositions, or treatments that indirectly or directly enhance, stimulate, or increase the body's immune response to cancer cells and / or reduce the side effects of other anticancer treatments. Therefore, immunotherapy is a treatment that directly or indirectly stimulates or enhances the immune system's response to cancer cells and / or reduces the side effects that other anticancer agents may cause. Immunotherapy is also known in the field as immunotherapy, biotherapy, biological response modifier therapy, and biological treatment. Common examples of known immunotherapy agents in the field include, but are not limited to, cytokines, cancer vaccines, monoclonal antibodies, and non-cytokine adjuvants. Alternatively, immunotherapy may include administering a dose of immune cells (T cells, NK cells, dendritic cells, B cells, etc.) to a patient, particularly including but not limited to allogeneic and / or autologous CAR therapies such as CAR-T cells, CAR-NK cells, and CAR-M cells.

[0046] Immunotherapy agents can be non-specific, meaning they generally enhance the immune system, making the body more effective at fighting the growth and / or spread of cancer cells; or they can be specific, meaning they target the cancer cells themselves. Immunotherapy regimens can combine non-specific and specific immunotherapy agents.

[0047] Nonspecific immunotherapeutic agents are substances that stimulate or indirectly improve the immune system. They have been used alone as a primary therapy in cancer treatment, or as a supplement to primary therapy, in which case they act as adjuvants to enhance the effects of other therapies, such as cancer vaccines. Nonspecific immunotherapeutic agents act on key immune system cells and induce secondary responses, such as increased production of cytokines and immunoglobulins. Alternatively, the agent itself may contain cytokines. Nonspecific immunotherapeutic agents are generally classified as either cytokine-based or non-cytokine-based adjuvants.

[0048] Many cytokines have been found to be used in cancer treatment, both as general non-specific immunotherapies aimed at enhancing the immune system and as adjuvants to other therapies. Suitable cytokines include, but are not limited to, interferons, interleukins, and colony-stimulating factors.

[0049] Interferons (IFNs) include common types such as IFN-α, IFN-β, and IFN-γ. IFNs can act directly on cancer cells, for example, by slowing their growth, promoting their development into more normal cells, and / or increasing their antigen production, thus making cancer cells more easily recognized and destroyed by the immune system. IFNs can also act indirectly on cancer cells, for example, by slowing angiogenesis, enhancing the immune system, and / or stimulating natural killer (NK) cells, T cells, and macrophages. Recombinant IFN-α is commercially available as Roferon (Roche Pharmaceuticals) and Intron A (Schering Corporation). IFN-α, alone or in combination with other immunotherapies or chemotherapy drugs, has shown therapeutic efficacy against a variety of cancers, including melanoma (including metastatic melanoma), kidney cancer (including metastatic kidney cancer), breast cancer, prostate cancer, and cervical cancer (including metastatic cervical cancer).

[0050] Interleukins include IL-2, IL-4, IL-11, and IL-12. Examples of commercially available recombinant interleukins include Proleukin® (IL-2; Chiron Corporation) and Neumega® (IL-12; Wyeth Pharmaceuticals). Interleukins, alone or in combination with other immunotherapies or chemotherapy agents, have shown efficacy in treating a variety of cancers, including kidney cancer (including metastatic kidney cancer), melanoma (including metastatic melanoma), ovarian cancer (including recurrent ovarian cancer), cervical cancer (including metastatic cervical cancer), breast cancer, colorectal cancer, lung cancer, brain cancer, and prostate cancer.

[0051] Colony-stimulating factors (CSFs) include granulocyte colony-stimulating factor (G-CSF or filgrastim), granulocyte-macrophage colony-stimulating factor (GM-CSF or saxagstim), and erythropoietin (eportin afa, dapoxetine). Several recombinant CSFs are commercially available, such as Neupogen® (G-CSF; Amgen), Neulasta (pefilgrastim; Amgen), Leukine (GM-CSF; Berlex), Procrit (erythropoietin; Ortho Biotech), Epogen (erythropoietin; Amgen), and Arnesp (erythropoietin). CSFs have shown therapeutic efficacy against cancers, including melanoma, colorectal cancer (including metastatic colorectal cancer), and lung cancer.

[0052] Non-cytokine adjuvants suitable for use in combinations disclosed herein include, but are not limited to, levamisole, aluminum hydroxide adjuvant (alum), BCG, incomplete Freund's adjuvant (IFA), QS-21, DETOX, keyhole hemocyanin (KLH), and dinitrophenol (DNP). Non-cytokine adjuvants in combination with other immunotherapeutic and / or chemotherapeutic agents have been shown to be effective against a variety of cancers, such as colon and colorectal cancer (levamisole); melanoma (BCG and QS-21); and renal and bladder cancer (BCG).

[0053] In addition to having specific or non-specific targets, immunotherapeutic agents can be active, that is, stimulating the body's own immune response; or they can be passive, that is, containing components of the immune system produced in vitro.

[0054] Active specific immunotherapy often involves the use of cancer vaccines. Developed cancer vaccines contain whole cancer cells, partial cancer cells, or one or more antigens derived from cancer cells. Cancer vaccines, alone or in combination with one or more immunotherapeutic or chemotherapeutic agents, are being investigated in the treatment of a variety of cancers, including melanoma, kidney cancer, ovarian cancer, breast cancer, colorectal cancer, and lung cancer.

[0055] Immunotherapy can include adoptive immunotherapy as described in Nicholas P. Restifo, Mark E. Dudley, and Steven A. Rosenberg, “Adoptive immunotherapy for cancer: harnessing the T cell response,” *Nature Reviews Immunology*, Volume 12, April 2012. In adoptive immunotherapy, the patient’s circulating lymphocytes or tumor-infiltrating lymphocytes are isolated in vitro, activated by interleukins such as IL-2 or transduced with tumor necrosis genes, and then re-administered (Rosenberg et al., 1988; 1989). The activated lymphocytes are preferably those that were previously isolated from the patient’s blood or tumor sample and activated (or “expanded”) in vitro. This form of immunotherapy has resulted in numerous cases of regression in melanoma and renal cell carcinoma. The immunotherapies described herein include allogeneic and / or autologous CAR therapy, well-known in the field, and particularly including, but not limited to, CAR-T cells, CAR-M cells, and CAR-NK cells.

[0056] Passive specific immunotherapy typically involves the use of one or more monoclonal antibodies that are specific to specific antigens found on the surface of cancer cells or to specific cell growth factors. Monoclonal antibodies can be used to treat cancer in a variety of ways, such as enhancing a subject's immune response to a specific type of cancer, interfering with cancer cell growth by targeting specific cell growth factors (such as those involved in angiogenesis), or enhancing the delivery of other anticancer agents to cancer cells when linked or conjugated with other anticancer agents (such as chemotherapeutic agents, radioactive particles, or toxins).

[0057] Currently used as cancer immunotherapy agents and suitable for inclusion in this disclosure, monoclonal antibodies include, but are not limited to, rituximab (Rituxan®), trastuzumab (Herceptin®), teimomab (Zevalin®), tosimomab (Bexxar®), cetuximab (C-225, Erbitux®), bevacizumab (Avastin®), gemtuzumab / ozomicin (Mylotarg®), alemtuzumab (Campath®), and BL22. Monoclonal antibodies are used to treat a variety of cancers, including breast cancer (including advanced metastatic breast cancer), colorectal cancer (including advanced and / or metastatic colorectal cancer), ovarian cancer, lung cancer, prostate cancer, cervical cancer, melanoma, and brain tumors. Other examples include immune checkpoint inhibitors.

[0058] The expression of "immune checkpoint proteins" is well-known in the field, referring to molecules expressed by T cells that can upregulate (stimulatory checkpoint molecules) or downregulate (inhibitory checkpoint molecules). Immune checkpoints constitute immune checkpoint pathways, such as the CTLA-4 and PD-1 dependent pathways (see Pardoll, 2012. Nature Rev Cancer 12:252-264; Mellman et al., 2011. Nature 480:480-489). Examples of inhibitory checkpoint molecules include A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO1, KIR, PD-1, LAG-3, TIM-3, TIGIT, and VISTA.

[0059] A2AR ("Adenosine A2A receptor") is considered an important checkpoint in cancer therapy: the presence of adenosine in the immune microenvironment leads to A2a receptor activation and induces a negative immune feedback loop, and the tumor microenvironment has a relatively high concentration of adenosine. B7-H3, also known as CD276, was initially understood as a co-stimulatory molecule but is now considered co-inhibitory. B7-H4, also known as VTCN1, is expressed by tumor cells and tumor-associated macrophages and is involved in tumor escape. BTLA ("B and T lymphocyte attenuation factor"), also known as CD272, has HVEM (herpesvirus entry mediator) as its ligand. BTLA is expressed on the surface of human CD8. + T cell differentiation is gradually downregulated during the differentiation process from naïve to effector cell phenotype. Tumor-specific human CD8 + T cells express high levels of BTLA. CTLA-4 ("Cytotoxic T-lymphocyte-associated protein 4"), also known as CD152, controls T cell proliferation upon expression on Treg cells. IDO1 ("Indoleamine 2,3-dioxygenase 1") is a tryptophan-catabolizing enzyme—an immunosuppressive enzyme. IDO1 is known to inhibit T and NK cells, generate and activate Tregs and myeloid-derived suppressor cells, and promote tumor angiogenesis. KIR ("Killer cell immunoglobulin-like receptor") is a receptor for MHC class I molecules on natural killer cells. LAG3 ("Lymphocyte activation gene-3") works by acting on Tregs and CD8+. + The direct inhibitory effect of T cells suppresses the immune response. The PD-1 ("programmed death 1") receptor has two ligands, PD-L1 and PD-L2. This checkpoint is the target of Merck's commercially available pembrolizumab. Targeting PD-1 allows for the restoration of immune function in the tumor microenvironment. TIM-3 ("T cell immunoglobulin domain and mucin domain 3") is activated on human CD4 cells. + TIM-3 is expressed on T cells and regulates Th1 and Th17 cytokines. It acts as a negative regulator of Th1 / Tc1 function by triggering cell death through its interaction with its ligand, galactolectin-9. VISTA ("V-domain Ig inhibitor of T cell activation") is primarily expressed on hematopoietic cells. Persistent expression of VISTA on tumor-associated leukocytes makes VISTA blockade effective in various solid tumors. TIGIT ("T cell immune receptor with Ig and ITIM domains") is an immune receptor present on some T cells and natural killer (NK) cells. TIGIT inhibits T cell activation in vivo.

[0060] "Immune checkpoint inhibitor" or "checkpoint blocking cancer immunotherapy agent" has the general meaning in the art and refers to any compound that inhibits the function of immunosuppressive checkpoint proteins. Inhibition includes reduction and complete blockade. Immune checkpoint inhibitors include peptides, antibodies, nucleic acid molecules, and small molecules. Preferred immune checkpoint inhibitors are antibodies that specifically recognize immune checkpoint proteins. Administration of immune checkpoint inhibitors as used in the context of this disclosure is intended to enhance CD8 in patients. + T cell proliferation, migration, persistence, and / or cytotoxicity. CD8 + T cells are a subset of T cells that express CD8 on their surface. They are MHC class I restricted and function as cytotoxic T cells. They are also known as cytotoxic T lymphocytes (CTLs), killer T cells, cytolytic T cells, CD8+ T cells, or cytotoxic T cells. The CD8 antigen is a member of the immunoglobulin superfamily and is a co-recognition element in MHC class I restricted interactions. Immune checkpoint inhibitors enhance CD8 expression. + The ability of T cells to kill can be determined by any well-known assay in the field. Typically, such assays are in vitro assays, in which CD8... + T cells and target cells (such as CD8 cells) + T cells recognize and / or lyse target cells. For example, they can target CD8+ cells. + The immune checkpoint inhibitors of this disclosure are selected for their ability to increase T-cell specific lysis by approximately 20% or more, preferably by at least 30%, at least 40%, at least 50%, or more. The classical cytotoxicity assay protocol is standard.

[0061] Typically, immune checkpoint inhibitors are agents that block immunosuppressive receptors expressed by activated T lymphocytes, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, also known as PD-1), or immunosuppressive receptors expressed by NK cells, such as members of the killer cell immunoglobulin-like receptor (KIR) family, or agents that block the major ligands of these receptors, such as PD-1 ligand CD274 (most notably PD-L1 or B7-H1).

[0062] Typically, checkpoint blockade cancer immunotherapy agents are antibodies.

[0063] In some implementations, the checkpoint blockade cancer immunotherapy agent is selected from the group consisting of: anti-PD1 antibody, anti-PDL1 antibody, anti-PDL2 antibody, anti-CTLA4 antibody, anti-TIM-3 antibody, anti-LAG3 antibody, anti-IDO1 antibody, anti-TIGIT antibody, anti-B7H3 antibody, anti-B7H4 antibody, anti-BTLA antibody, and anti-B7H6 antibody.

[0064] Examples of anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies are described in U.S. Patent Nos. 7,488,802; 7,943,743; 8,008,449; 8,168,757; 8,217,149, and PCT Publication Patent Application Nos. WO03042402, WO2008156712, WO2010089411, WO2010036959, WO2011066342, WO2011159877, WO2011082400, and WO2011161699. In some embodiments, the PD-1 blocker comprises an anti-PD-L1 antibody (such as atezolizumab, avelumab, or durvalumab). In other embodiments, the PD-1 blocker comprises an anti-PD-L2 antibody. In some other embodiments, PD-1 blockers include anti-PD-1 antibodies and similar binding proteins, such as nivolumab (MDX 1106, BMS936558, ONO 4538), a fully human IgG4 antibody that binds to and blocks PD-1 activation by its ligands PD-L1 and PD-L2; pembrolizumab (MK-3475 or SCH 900475), a humanized monoclonal IgG4 anti-PD-1 antibody; CT-011, a humanized antibody that binds to PD-1; AMP-224, a fusion protein of B7-DC; the Fc portion of the antibody; and BMS-936559 (MDX-1105-01) for PD-L1 (B7-H1) blockade.

[0065] Examples of anti-CTLA-4 antibodies are described in U.S. Patent Nos. 5,811,097; 5,811,097; 5,855,887; 6,051,227; 6,207,157; ​​6,682,736; 6,984,720; and 7,605,238. One anti-CTLA-4 antibody is tremelimumab (ticilimumab, CP-675,206). In some embodiments, the anti-CTLA-4 antibody is ipilimumab (also known as 10D1, MDX-D010), a fully human monoclonal IgG antibody that binds to CTLA-4.

[0066] Other immune checkpoint inhibitors include lymphocyte activation gene-3 (LAG-3) inhibitors, such as IMP321, a soluble Ig fusion protein (Brignone et al., 2007, J. Immunol. 179:4202-4211).

[0067] Other immune checkpoint inhibitors include B7 inhibitors, such as B7-H3 and B7-H4 inhibitors. In particular, the anti-B7-H3 antibody MGA271 (Loo et al., 2012, Clin. Cancer Res. July 15 (18) 3834).

[0068] This also includes TIM3 ("T-cell immunoglobulin domain and mucin domain 3") inhibitors (Fourcade et al., 2010, J. Exp. Med. 207:2175-86 and Sakuishi et al., 2010, J. Exp. Med. 207:2187-94). The natural ligand for TIM-3 is galectin 9 (Gal9). Therefore, as used herein, the term "TIM-3 inhibitor" refers to a compound, substance, or composition capable of inhibiting TIM-3 function. For example, inhibitors can inhibit the expression or activity of TIM-3, modulate or block the TIM-3 signaling pathway, and / or block the binding of TIM-3 to galectin-9. Antibodies specific to TIM-3 are well known in the field and are generally those described in WO2011155607, WO2013006490, and WO2010117057.

[0069] In some implementations, the immune checkpoint inhibitor is an indoleamine 2,3-dioxygenase (IDO) inhibitor, preferably an IDO1 inhibitor. Examples of IDO inhibitors are described in WO 2014150677. Examples of IDO inhibitors include, but are not limited to, 1-methyl-tryptophan (IMT), β-(3-benzofuranyl)-alanine, β-(3-benzo(b)thiophenyl)-alanine, 6-nitro-tryptophan, 6-fluoro-tryptophan, 4-methyl-tryptophan, 5-methyl-tryptophan, 6-methyl-tryptophan, 5-methoxy-tryptophan, 5-hydroxy-tryptophan, indole-3-methanol, 3,3'-diindolemethane, epigallocatechin gallate, 5-Br-4-Cl-indole-1,3-diacetate, 9-vinylcarbazole, acemetidine, 5-bromo-tryptophan, 5-bromoindole diacetate, 3-amino-naphthoic acid, pyrrolidine dithiocarbamate, 4-phenylimidazole, brassinosteroids derivatives, thiohydantoin derivatives, β-carboline derivatives, or brassinosteroids derivatives. The preferred IDO inhibitor is selected from 1-methyl-tryptophan, β-(3-benzofuranyl)-alanine, 6-nitro-L-tryptophan, 3-amino-naphthoic acid, and β-[3-benzo(b)thienyl]-alanine, or their derivatives or prodrugs.

[0070] In some implementations, immune checkpoint inhibitors are anti-TIGIT (T-cell immunoglobulin and ITIM domain) antibodies.

[0071] According to a specific implementation scheme, the anticancer treatment according to this disclosure is an immune checkpoint inhibitor, preferably selected from antiPD-1 antibodies and antiPD-L1 antibodies.

[0072] In a preferred embodiment, the checkpoint blocking cancer immunotherapy agent is a PD-1 blocking antibody, such as nivolumab or pembrolizumab.

[0073] Compound of formula (I) Compounds of formula (I) can be synthesized using techniques conventionally used by those skilled in the art.

[0074] According to the preferred embodiment, the compound of formula (I) is selected from the group consisting of: N-(4-(3-((4-(oct-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazo-2-yl)acetamide, referred herein as "BPR001-615" of formula (II) (also referred to herein as PB615): [Formula II]: N-(4-(3-((4-(hex-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB614"; N-(4-(3-((4-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB608"; N-(4-(3-((4-(cyclohexylethynyl)phenyl)sulfonamide)phenyl)thiazo-2-yl)acetamide, referred to in this article as "PB612"; N-(4-(3-((4-ethynylphenyl)sulfonylamino)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB610"; N-(4-(3-((4-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide, referred to in this paper as "PB671"; N-(4-(3-((4-(dec-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazo-2-yl)acetamide, referred to in this article as "PB672"; N-(4-(3-((4-(4-phenylbut-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB673"; N-(4-(3-((3-(oct-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazo-2-yl)acetamide, referred to in this article as "PB617"; N-(4-(3-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamide)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB619"; N-(4-(3-((3-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide, referred to in this article as "PB620"; N-(4-(3-((3-ethynylphenyl)sulfonylamino)phenyl)thiazolyl-2-yl)acetamide, referred to in this article as "PB621"; N-(3-(2-(methylamino)thiazolyl-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide, referred to in this article as "PB611"; 4-(oct-1-yn-1-yl)-N-(3-(2-(phenylamino)thiazolyl-4-yl)phenyl)benzenesulfonamide, referred to herein as "PB613"; and N-(3-(2-aminothiazolyl-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide, referred to herein as "PB622".

[0075] The methods for synthesizing these specific preferred compounds are disclosed in the following experimental section.

[0076] The compounds of formula (I) according to this disclosure may be in pharmaceutically acceptable salt form. Pharmaceutically acceptable salts include their acid addition salts and base salts.

[0077] Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include acetates, aspartates, benzoates, benzenesulfonates, bicarbonates / carbonates, bisulfates / sulfates, borates, camphorsulfonates, citrates, ethanedisulfonates, ethanesulfonates, formates, fumarates, gluconate, gluconate, glucuronates, hexafluorophosphates, adipoxate, hydrochlorides / chlorides, hydrobromides / bromines, hydroiodates / iodides, hydroxyethanesulfonates, lactates, malates, maleates, malonates, methanesulfonates, methyl sulfates, naphthates, 2-naphthalenesulfonates, nicotinates, nitrates, orotates, oxalates, palmitates, dihydroxynaphthalates, phosphates / hydrogen phosphates / dihydrogen phosphates, saccharinates, stearates, succinates, tartrates, toluenesulfonates, and trifluoroacetates, as well as sinetes.

[0078] Suitable base salts are formed from bases that form non-toxic salts. Examples include aluminum salts, arginine salts, benzyl benzoate salts, calcium salts, choline salts, diethylamine salts, diolamine salts, glycine salts, lysine salts, magnesium salts, meglumine salts, ethanolamine salts, potassium salts, sodium salts, tromethamine salts, and zinc salts. Hemisalts of acids and bases can also be formed, such as hemisulfates and hemicalcium salts. For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0079] The compounds used in the context of this disclosure may exist in unsolvated and solvated forms. The term "solvate" describes a stoichiometric complex comprising a benzylsulfonamide thiazole compound and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol). When the solvent is water, the term "hydrate" is used. Complexes such as inclusion complexes and drug-host inclusion complexes are also included, wherein, unlike the solvates described above, the drug and host are present in stoichiometric or non-stoichiometric amounts. Drug complexes containing two or more organic and / or inorganic components are also included, which may exist in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).

[0080] Therefore, compounds of formula (I) include references to their salts, solvates, and complexes, as well as references to solvates and complexes of their salts. Compounds of formula (I) include all their polymorphs and crystal habits, prodrugs and their isomers (including optical, geometric, and tautomers), and isotopically labeled compounds of formula (I).

[0081] Therapeutic uses As described above, the anticancer treatment and compounds of formula (I), particularly compounds of formula (II), according to this disclosure are used to treat cancer in patients.

[0082] Therefore, this disclosure provides a method for treating cancer, comprising administering to a patient in need a therapeutically effective amount of anticancer treatment and a compound of formula (I) as defined above, particularly a compound of formula (II).

[0083] This disclosure further provides the use of compounds of formula (I), and especially compounds of formula (II), in the preparation of medicaments for treating cancer, whether as a monotherapy or in combination as disclosed.

[0084] According to this disclosure, anticancer treatment and compound (I), particularly compound (II), are administered to a patient simultaneously, separately, or in any order. According to a particular embodiment, anticancer treatment is administered after compound (I), particularly compound (II). In other words, anticancer treatment is administered to a patient who has already received compound (I), particularly compound (II). According to another particular embodiment, compound (I), particularly compound (II), is administered after anticancer treatment. In other words, compound (I), particularly compound (II), is administered to a patient who has already received anticancer treatment.

[0085] The terms "subject" and "patient" refer to a person or animal suffering from cancer. Typically, a patient is a mammal. A patient can be, for example, a human, a feline such as a cat, a canine such as a dog, or an equine such as a horse. Preferably, the patient is a human.

[0086] To avoid ambiguity, the term "treatment" as used herein includes curative, palliative, and preventative treatment. "Treatment" aims to reverse, alleviate, or inhibit the progression of a disorder or condition to which the term applies, or to prevent the progression of one or more symptoms of a disorder or condition to which the term applies. Specifically, in certain embodiments, when referring to a cancer disorder, the term "treatment" may refer to slowing or stopping tumor growth, reducing tumor size, eradicating a tumor, or preventing metastatic development.

[0087] The term "cancer" in this article refers to a physiological condition in a subject characterized by unregulated or disordered cell growth or death. The term "cancer" includes solid tumors and hematologic malignancies.

[0088] Generally, the combination of uses according to this disclosure is applicable to various cancer-originating organs (such as breast, colon, stomach, rectum, pancreas, lung, skin, head and neck, bladder, ovary, prostate) and also to various cancer cell types (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, melanoma, etc.).

[0089] In a specific implementation plan, the patient has a solid cancer selected from the following groups: skin cancer (e.g., melanoma, non-melanoma skin cancer), colorectal cancer, adrenocortical carcinoma, anal cancer, bile duct cancer (e.g., perihepatic bile duct cancer, distal bile duct cancer, intrahepatic bile duct cancer), bladder cancer, bone cancer (e.g., osteoblastoma, osteosarcoma, chondrosarcoma, fibrosarcoma, malignant fibrous histiocytoma), sarcoma such as liposarcoma and soft tissue sarcoma, brain and central nervous system cancers (e.g., meningioma, astrocytoma, oligodendroglioma, ependymoma, glioma, medulloblastoma, ganglioglioma, germ cell tumor, craniopharyngioma), breast cancer (e.g., ductal carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma, lobular carcinoma in situ), cervical cancer, endometrial cancer (e.g., endometrial adenocarcinoma, adenosine carcinoma, papillary serous adenocarcinoma), esophageal cancer, gallbladder cancer (mucinous adenocarcinoma, etc.). Small cell carcinoma, gastrointestinal carcinoid tumors (such as choriocarcinoma, destructive chorioadenoma), kidney cancer (such as renal cell carcinoma), laryngeal and hypopharyngeal cancer, liver cancer (such as hepatic adenoma, hepatocellular carcinoma), lung cancer (such as small cell lung cancer, non-small cell lung cancer), mesothelioma, nasal cavity and paranasal sinus cancer (such as olfactory neuroblastoma, midline granuloma), nasopharyngeal carcinoma, neuroblastoma, oral and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma (such as embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, pleomorphic rhabdomyosarcoma), salivary gland cancer, gastric cancer, testicular cancer (such as seminoma, non-seminomatous germ cell carcinoma), thymic cancer, thyroid cancer (such as follicular carcinoma, anaplastic carcinoma, poorly differentiated carcinoma, medullary thyroid carcinoma), vaginal cancer, vulvar cancer, and uterine cancer (such as uterine leiomyosarcoma).

[0090] In certain implementation schemes, patients have blood cancers such as leukemia, lymphoma (such as Hodgkin lymphoma or non-Hodgkin lymphoma), and myeloma.

[0091] As shown in the experimental section below, the compounds according to this disclosure have demonstrated high efficacy against both sensitive and drug-resistant cancer cell lines from melanoma and colorectal cancer. Therefore, according to another specific embodiment, the cancers treated according to this disclosure are selected from skin cancer and colorectal cancer.

[0092] According to the preferred embodiment, the cancer treated according to this disclosure is colorectal cancer, gastric cancer, pancreatic cancer, breast cancer, lung cancer, or skin cancer (preferably melanoma).

[0093] Not wanting to be bound by theory, the inventors believe that the compound of formula (I) described herein makes the tumor immunogenic, i.e., detectable by the immune system, thereby allowing for enhanced anticancer effects of combined anticancer therapy.

[0094] Therefore, according to a specific embodiment, the cancer described in this disclosure is a non-immunogenic tumor. In this document, "non-immunogenic tumor" means a tumor that does not elicit a T-cell response. Those skilled in the art are familiar with this concept and know how to determine whether a tumor is immunogenic (see, for example, Wang et al.). Elife 8 (2019): e49020). This type of tumor is often associated with the following: - A small number of tumor-infiltrating lymphocytes, with a correspondingly low density of tumor-infiltrating lymphocytes, whether at the tumor periphery or the tumor center, as published under International Application No. WO2007 / 045996 or as determined by Immunoscore®; - Exhausted CD8 + T cell population—also known as "Tex cells" (see Wherry, E. John, and Makoto Kurachi, Nature Reviews Immunology 15.8 (2015): 486-499), which can be found by Bengsch et al. Immunity Identification was performed as shown in 48.5 (2018): 1029-1045; - Limited tumor antigen presentation (as shown by Wang (2019)); - Most M2 macrophages and myeloid-derived suppressor cells; and / or - Type 2 inflammatory tumor microenvironment (see Gajewski et al.) Tumor immune microenvironment in cancer progression and cancer therapy (2017): 19-31 orTrujillo et al. Cancer immunology research 6.9 (2018): 990-1000).

[0095] According to another embodiment, cancer "resistance" to immunotherapy, as defined in this disclosure, means that the patient does not respond or responds poorly to immunotherapy, particularly to immune checkpoint inhibitor monotherapy.

[0096] As used in this article, "responder" refers to a patient who will achieve a response, i.e., a patient whose cancer is eradicated, reduced, or stabilized after treatment. Non-responders or treatment-resistant patients include those whose cancer has not shown reduction or stabilization after immunotherapy, particularly immune checkpoint therapy.

[0097] The inventors further demonstrated that the combination therapy according to this disclosure triggers significant tumor cell suppression in cancer lines from tumors overexpressing GRP78.

[0098] GRP78 overexpression has been shown to be associated with poor prognosis in a variety of cancers, such as ovarian cancer (see Samanta et al.). Scientific reports10.1 (2020): 1-12), melanoma (Shimizu et al.). Pathology Oncology Research 23.1 (2017): 111-116), Lung cancer (Xia et al.). Journal of Translational Medicine 19.1 (2021): 1-14), gastric cancer (Zhang et al.). Clinical & experimental metastasis 23.7 (2006): 401-410), breast cancer (Oncology letters 10.4 (2015): 2149-2155), esophageal cancer (Zhao et al.). Digestive diseases and sciences 60.9 (2015):2690-2699), pancreatic cancer (Tong et al.). Pancreatology 21.7 (2021): 1378-1385) or colorectal cancer (Thornton et al.). International journal of cancer 133.6 (2013): 1408-1418). The combination according to this disclosure can significantly reduce GRP78 levels.

[0099] Therefore, the combination therapy according to this disclosure is particularly beneficial for patients with high GRP78 levels who are therefore identified as having a poor prognosis.

[0100] Therefore, according to a further implementation scheme, patients according to this disclosure overexpress GRP78.

[0101] "78 kDa glucose-regulated protein" or "GRP78," also known as "binding immunoglobulin protein" (BiP) or "heat shock 70 kDa protein 5" (HSPA5), is a protein encoded by the HSPA5 gene in humans. It is an endoplasmic reticulum chaperone protein that plays a crucial role in protein folding and quality control within the endoplasmic reticulum lumen. The sequence of GRP78 is available in the Uniprot database under reference number P11021.

[0102] "Overexpression" means that the level of GRP78 measured in a biological sample obtained from a patient is significantly higher than the level measured in a control sample. Typically, the control sample can be a sample obtained from a control population or control tissue. The control population usually consists of healthy subjects, i.e., subjects without cancer or any other disease. The control tissue usually consists of healthy tissue, i.e., tissue unaffected by disease. The control tissue is usually obtained from the patient themselves. Several techniques that allow for the determination of whether a gene / protein is overexpressed relative to a control sample are known to those skilled in the art. Such routinely used techniques are familiar to those skilled in the art. Several studies on the assessment of GRP78 levels have been published (see, for example, Huang et al. (2018)). International Journal of Clinical and Experimental Pathology , 11 (11), 5223). Generally, GRP78 levels are considered "overexpressed" when the levels are 1.5 times, preferably 1.7 times, more preferably 2 times higher than those measured in the control group.

[0103] Typically, the measured GRP78 level is either the circulating GRP78 level or the intratumoral GRP78 level.

[0104] "Circulating GRP78" refers to the GRP78 protein present in the circulation of a patient's blood, typically in the cell-free fraction of the patient's blood (plasma / serum). Circulating GRP78 protein levels are usually measured by assessing the amount of GRP78 in a blood sample (usually a plasma / serum sample) obtained from the patient. A control used to determine whether circulating GRP78 levels are overexpressed is typically a measurement of GRP78 levels in a blood sample from a control group.

[0105] "Intratumoral GRP78" refers to the GRP78 protein expressed within a patient's tumor. GRP78 protein levels are typically measured by assessing the amount of GRP78 expressed in a tumor sample obtained from the patient (usually a tumor biopsy). A control used to determine whether intratumoral GRP78 levels are overexpressed is typically a measurement of GRP78 levels in a control tissue (i.e., healthy tissue from the patient).

[0106] Those skilled in the art are familiar with many commonly used techniques for determining the expression levels of proteins such as GRP78.

[0107] These methods typically involve contacting the biological sample to be analyzed with a reagent capable of specifically binding to a target protein. This reagent is usually a polyclonal or monoclonal antibody. The presence of the protein is then detected by a standard immunoassay method (also known as "Western blotting") after the protein has been separated by electrophoresis, or by an immunoassay method (also known as "ELISA") using direct, indirect, competitive, or immunocapture methods. The complex formed between the protein and the antibody targeting the protein is typically detected and quantified by measuring the enzymatic reaction that produces a colored, chemiluminescent, or fluorescent product, resulting in a specific staining pattern with a staining percentage. Generally, "strong staining" is defined as ≥50% positive staining of tumor cells, "moderate staining" as 10% to <50% positive staining of tumor cells, and "weak staining" as <10% positive staining of tumor cells (Samanta et al, 2020).

[0108] Currently, there are several kits available for measuring plasma / serum GRP78 levels. For example, the ELISA kit sold by Enzo LifeSciences under reference number ADI-900-214 can be used.

[0109] The level of GRP78 within a tumor can also be determined by measuring the density of cells expressing GRP78. Typically, methods for measuring the density of GRP78-expressing cells involve contacting a tumor tissue sample with at least one selective binder capable of selectively interacting with GRP78. The selective binder can be a polyclonal or monoclonal antibody, an antibody fragment, a synthetic antibody, or other protein-specific reagents such as nucleic acids or peptide aptamers. Many GRP78-specific antibodies are known to those skilled in the art. Many of these antibodies are commercially available. Immunohistochemistry is particularly well-suited for assessing GRP78 cell density. Typically, a tumor tissue sample is first incubated with an anti-GRP78-labeled antibody. After washing, the labeled antibody binding to GRP78 is displayed using appropriate techniques, depending on the type of label carried by the labeled antibody, such as radioactive, fluorescent, or enzyme-labeled.

[0110] GRP78 levels can also be measured by determining the amount of mRNA produced by the HSPA5 gene. Methods for determining mRNA levels are well-known in the field. For example, nucleic acids contained in the sample are first extracted according to standard methods, such as using lysins or chemical solutions, or using nucleic acid-binding resins as directed by the manufacturer. The extracted mRNA is then detected by hybridization (e.g., Northern blotting) and / or amplification (e.g., RT-PCR). Quantitative or semi-quantitative RT-PCR is the preferred method.

[0111] Therefore, according to a particular embodiment, this disclosure provides a method for treating a patient with cancer, including the step of measuring the level of GRP78 in a tumor or blood / plasma / serum sample obtained from the patient, and then, if the patient is identified as overexpressing GRP78, administering a therapeutically effective amount of anticancer treatment and a compound of formula (I) as defined above, particularly a compound of formula (II).

[0112] The compounds used in the context of this disclosure can be administered via any suitable route. Those skilled in the art know which route of administration and corresponding dosage to use. Useful compounds used in the context of this disclosure are typically administered parenterally (e.g., intravenously, intramuscularly, or subcutaneously) or orally.

[0113] Another aspect of this disclosure is the compound of formula (I): Formula (I) in - R1 represents H, methyl, phenyl, or acetyl; - R2 stands for H, or C2-C 10 Alkyl, cycloalkyl, or hydroxyalkyl; and The alkynyl chain connected to R2 is attached to the benzene ring at the 3 or 4 position. Its use in treating GRP78-overexpressing tumors in patients in need.

[0114] In a particular embodiment, "GRP78 overexpressing tumor" refers to a patient tumor characterized by GRP78-positive staining in at least 1%, preferably at least 10%, of tumor cells in a tumor sample. Such staining can be measured by methods well-known in the art, particularly as described in Samanta et al., 2020.

[0115] In one implementation, a "GRP78 overexpressing tumor" can be characterized by measuring intratumoral or circulating GRP78 expression as described above.

[0116] Compounds of formula (I), and especially compounds of formula (II), whether as monotherapy or in combination therapy as disclosed herein, are useful for patients with tumors that overexpress GRP78, whether they are high-GRP78 or low-GRP78 tumors.

[0117] In one embodiment, the compound of formula I or formula II is used to treat GRP78-positive tumors in patients in need, wherein the tumors are high-GRP78 tumors.

[0118] "High GRP78 tumor" refers to a patient's tumor characterized by at least 50% of tumor cells in a sample obtained from the tumor being positively stained with GRP78.

[0119] In one embodiment, the compound of formula I or formula II is used to treat GRP78-positive tumors in patients in need, wherein the tumors are low-GRP78 tumors.

[0120] "Low GRP78 tumor" means a patient's tumor characterized by 1% to less than 50%, preferably 10% to less than 50%, of tumor cells in a sample obtained from the tumor as being positively stained for GRP78.

[0121] In a particular embodiment, the compound of formula (I) is used to treat GRP78-overexpressing tumors in patients in need, wherein the patients have low-GRP78 tumors, and wherein the compound of formula (I) is the compound of formula (II) above, BPR001-615.

[0122] In one embodiment, the patient treated with the compound of formula I, particularly the compound of formula (II) BPR001-615, has a low GRP78 tumor, i.e., the patient's tumor shows 1% to less than 50%, preferably 10% to less than 50% positive tumor cells by immunohistochemical staining for GRP78, as determined by Samanta et al. 2020, meaning that 1% to less than 50%, preferably 10% to less than 50% of the tumor cells are stained positive, as described in Samanta et al. 2020.

[0123] In one implementation, the patient to be treated with combination therapy has a high GRP78 tumor, meaning that the patient's tumor shows at least 50% positive tumor cells when stained with GRP78 by immunohistochemistry, as determined by Samanta et al. 2020, which means that 50% to less than 100% of the tumor cells are stained positive, as described in Samanta et al. 2020.

[0124] As described herein, compounds of formula (I), and especially compounds of formula (II), are used to treat patients in need of GRP78-positive tumors, whether low-GRP78 or high-GRP78 tumors, whether used alone as a monotherapy or in combination with an anticancer agent, such combinations being described in detail in this disclosure.

[0125] This disclosure will be further illustrated by the following drawings and embodiments. However, these embodiments and drawings should not be construed as limiting the scope of the invention in any way.

[0126] Example Synthesis of compound (I): Chemical Synthesis and Characterization Methanol, ethanol, pyridine, DMF, ethyl acetate, diethyl ether, and dichloromethane were purchased from Sigma-Aldrich. DMF was dried by vacuum distillation over MgSO4, pyridine and triethylamine by vacuum distillation over CaH2, while methanol, ethanol, diethyl ether, ethyl acetate, and dichloromethane were used as received. All chemicals were purchased from Aldrich, Merck, or Alfa Aesar and used without further purification. Thin-layer chromatography (TLC) was performed on pre-coated Merck 60 GF254 silica gel plates, first observed under UV light (254 nm and 365 nm), then developed by spraying (ninhydrin or H2SO4 / EtOH). 1 H and 13 C10 NMR spectra were recorded on a Bruker Advance 200 MHz spectrometer or a Bruker Advance 400 MHz spectrometer. Mass spectrometry (ESI-MS) was recorded on a Bruker (Daltonics Esquire 3000+). HRMS spectra were recorded on a Thermo Fisher Q Exactive (ESI-MS) at a resolution of m / z 200 (140,000). Compound purity was further determined by HPLC analysis on a JASCO PU-2089 instrument using a Supelco Ascentis Express C18 column, 100 mm × 46 mm, 5 μM. UV detection: 214; 254; 280; 360 nm. Eluent A: water containing 1‰ formic acid; Eluent B: CH3CN containing 1‰ formic acid. Method 1: 0–1 min: 0% B; 1–10 min: 0–100% B; 10–15 min: 100% B. Method 2: 0-2 min: 10% B; 2-9 min: 10-100% B; 9-18 min: 100% B. Method 3: 0-1 min: 30% B; 1-6 min: 30-100% B; 6-8.5 min: 100% B.

[0127] Sonogashira Coupling General Program Under argon atmosphere, Pd(PPh3)4 (15% mol.), cuprous iodide (15% mol.), and the corresponding alkyne (5 equivalents) were added to a suspension of the haloaryl derivative (5a: N-(4-(3-((4-bromophenyl)sulfonamide)phenyl)thiazol-2-yl)acetamide or 6: N-(4-(3-((3-bromophenyl)sulfonamide)phenyl)thiazol-2-yl)acetamide) in an Et3N:benzene (1 / 1, [0.17M]) mixture. The resulting mixture was stirred at 80 °C until the starting material was completely converted (approximately 2 hours). The reaction mixture was then cooled to room temperature, and all volatiles were removed under reduced pressure. The crude product was purified by rapid silica gel chromatography to obtain the pure corresponding coupling product.

[0128] Synthesis Procedure and Characterization N-(4-(3-((4-(oct-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (BPR001-615). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (400.0 mg, 0.88 mmol), Pd(PPh3)4 (152.5 mg, 15% mol.), cuprous iodide (25.1 mg, 15% mol.), and oct-1-yne (653.2 µL, 4.43 mmol). Rapid purification by silica gel chromatography (CH2Cl2:EtOAc; 100:0 to 70:30) yielded a white-yellow powdery alkyne 1 (330.1 mg, 78%). 1 H NMR (CD3OD, 200 MHz): δ 0.97 – 0.78 (m, 3H, H 23 ), 1.62 – 1.15 (m, 9H,H 22 H 21 H 20 and H 19 ), 2.19 (s, 3H, H1), 2.34 (t, J = 6.8 Hz, 2H, H 18 ), 6.97 (ddd, J =8.0, 2.1 and 0.9 Hz, 1H, H9), 7.26 – 7.14 (m, 2H, H4 and H 10 ), 7.38 (d, J = 8.5 Hz, 2H, H 14 ), 7.56 (d, J = 7.9 Hz, 1H, H 11 ), 7.74 – 7.65 (m, 3H, H7 and H) 13 ). 13C NMR (CD3OD, 50 MHz): δ 14.5, 20.2, 22.7, 23.7, 29.7, 29.8, 32.6, 80.4, 95.4, 109.3,120.1, 121.7, 123.6, 128.4 (2C), 130.3, 130.5, 132.9 (2C), 137.1, 139.3,139.7, 150.4, 159.6, 171.0. HRMS-ESI (m / z) [M+H] + C 25 H 28 Calculated value of N3O3S2: 482.1567; Measured value: 482.1565. HPLC (λ) 280 Purity: 97.8%; t R : 8.86 min (Method 1).

[0129] N-(4-(3-((4-(hex-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB614). Under argon atmosphere, Pd(PPh3)4 (57.8 mg, 15% mol.) and cuprous iodide (9.5 mg, 15% mol.) were added to a solution of bromoaryl 5a (150.0 mg, 0.33 mmol) in a mixture of triethylamine (1 mL) and benzene (1 mL). Hexyl-1-yne (188.0 µL, 1.66 mmol) was added to the medium, and the resulting mixture was stirred at 80 °C for 2 h (TLC monitoring). The reaction mixture was cooled to room temperature, and all volatiles were removed under reduced pressure. Purification by silica gel column chromatography (CH2Cl2:EtOAc; 100:0 to 70:30) yielded a grayish-white powdery alkyne 7 (117.2 mg, 78%). 1 H NMR (CD3OD, 200 MHz): δ 0.91 (t, J = 7.1 Hz, 3H, H 21 ), 1.62 – 1.35 (m, 4H, H 20 and H 19 ), 2.20 (s, 3H, H1), 2.37 (t, J = 6.8 Hz, 2H, H 18 ), 6.97 (ddd, J = 8.0, 2.2, 0.9 Hz, 1H, H9), 7.27 – 7.16 (m, 2H, H4 and H 10 ), 7.39 (d,J = 8.5 Hz, 1H, H 14 ), 7.57 (dt, J = 7.8, 1.2 Hz, 1H, H 11 ), 7.76 – 7.64 (m, 2H, H7 and H 13 ). 13 C NMR (CD3OD, 50 MHz): δ 14.1, 19.8, 22.7, 23.1,31.9, 80.4, 95.4, 109.3, 120.2, 121.8, 123.6, 128.4 (2C), 130.4, 130.5, 132.9(2C), 137.2, 139.3, 139.7, 150.5, 159.6, 171.0. HRMS-ESI (m / z) [M+H] + C 23 H 24 Calculated value of N3O3S2: 454.1254; Measured value: 454.1249. HPLC (λ) 280 Purity > 99%; t R : 8.08 min (Method 1).

[0130] N-(4-(3-((4-(3-hydroxypropyl-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB608). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (300.0 mg, 0.66 mmol), Pd(PPh3)4 (114.4 mg, 15% mol.), cuprous iodide (18.9 mg, 15% mol.), and propargyl alcohol (190.4 µL, 3.30 mmol). Rapid purification by silica gel chromatography (CH2Cl2:CH3OH; 100:0 to 95:5) yielded a white-yellow powdery alkyne 8 (201.9 mg, 72%). 1 H NMR (CD3OD, 200 MHz): δ 2.20 (s, 1H, H1), 4.36 (s, 2H, H 18 ), 6.97(ddd, J = 8.0, 2.2, 1.0 Hz, 1H, H9), 7.34 – 7.14 (m, 2H, H4 and H 10 ), 7.51 – 7.42(m, 2H, H 14 ), 7.63 – 7.53 (m, 1H, H 11), 7.78 – 7.66 (m, 3H, H7 and H) 13 ). 13 C NMR (CD3OD, 50 MHz): δ 22.7, 51.2, 84.0, 92.7, 109.3, 120.2, 121.8, 123.7, 128.5(2C), 129.1, 130.6, 133.1(2C), 137.2, 139.3, 140.6, 150.5, 159.6, 171.1.HRMS-ESI (m / z) [M+H] + C 20 H 18 Calculated value of N3O4S2: 428.0733; Measured value: 428.0736. HPLC (λ) 254 Purity 99.1%; t R : 5.76 min (Method 2).

[0131] N-(4-(3-((4-(cyclohexylethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB612). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (110 mg, 0.24 mmol), Pd(PPh3)2Cl2 (25.7 mg, 15% mol.), cuprous iodide (7.0 mg, 15% mol.), and cyclohexylacetylene (159.4 µL, 1.22 mmol). Rapid purification by silica gel chromatography (cyclohexane:EtOAc; 100:0 to 70:30) yielded a white-yellow powdery alkyne 9 (55 mg, 47%). 1 H NMR (acetone- d 6 (200 MHz) δ 1.58 – 1.22 (m, 6H, H 20 and H 21 ), 1.91 – 1.61 (m,4H, H 19 ), 2.28 (s, 3H, H1), 2.70 – 2.49 (m, 1H, H 18 ), 7.09 (ddd, J = 8.0, 2.3,1.1 Hz, 1H, H9), 7.26 (t, J = 7.9 Hz, 1H, H 10 ), 7.38 (s, 1H, H4), 7.48 (d, J = 8.4Hz, 2H, H14 ), 7.61 (d, J = 7.7 Hz, 1H, H 11 ), 7.75 (d, J = 8.5 Hz, 2H, H 13 ), 7.85(t, J = 1.9 Hz, 1H, H7), 9.10 (s, 1H, NH 磺酰胺 ), 11.17 (s, 1H, NH 乙酰基 ). 13 C NMR (acetone- d 6 (50 MHz) δ 22.9, 25.4 (2C), 26.5, 30.3, 33.2 (2C), 80.3, 99.0, 108.8,119.6, 121.2, 123.1, 128.2 (2C), 129.7, 130.3, 132.7 (2C), 136.8, 139.0,139.6, 149.7, 159.0, 169.2. HRMS-ESI (m / z) [M+H] + C 25 H 26 Calculated value of N3O3S2: 480.1410; Measured value: 480.1413. HPLC (λ) 254 Purity: 98.9%; t R 6.23 min (Method 2).

[0132] N-(4-(3-((4-ethynylphenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide(PB610). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (300.0 mg, 0.66 mmol), Pd(PPh3)4 (114.4 mg, 15% mol.), cuprous iodide (18.9 mg, 15% mol.), and trimethylsilylacetylene (281.9 µL, 1.98 mmol). After the reaction was complete (approximately 2 hours), the mixture was filtered through a silica gel pad (eluted with CH2Cl2 / EtOAc 70:30), and the filtrate was concentrated under reduced pressure. The black residue was dissolved in CH2Cl2 / CH3OH (1:1; 2 mL: 2 mL), and K2CO3 (456.1 mg, 3.3 mmol) was added to the mixture. The resulting suspension was stirred at room temperature for 5 hours, adsorbed onto silica gel, and then purified by rapid silica gel chromatography (CH2Cl2 / CH3OH; 100:0 to 95:0) to obtain yellow-brown powdery alkyne 11 (88.2 mg, 34%). 1 H NMR (CD3OD, 200 MHz): δ 2.20 (s, 3H, H1), 3.70 (s, 1H, H 17 ), 6.97 (ddd, J = 7.9, 2.3, 1.1 Hz,1H, H9), 7.30 – 7.14 (m, 2H, H 10 (and H4), 7.62 – 7.44 (m, 3H, H) 11 and H 14 ), 7.80 –7.67 (m, 3H, H7 and H) 13 ). 13 C NMR (CD3OD, 50 MHz): δ 22.7, 82.4, 82.9, 109.4, 120.2,121.8, 123.7, 128.4 (3C), 130.6, 133.6 (2C), 137.2, 139.2, 141.0, 150.4,159.6, 171.0. HRMS-ESI (m / z) [M+H] + C 19 H 16 Calculated N3O3S2: 398.0628; Measured: 298.0626. HPLC (λ) 254 Purity: 98.9%; t R 6.23 min (Method 2).

[0133] N-(4-(3-((4-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetyl amine (PB671). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (113.0 mg, 0.25 mmol), Pd(PPh3)4 (22.0 mg, 7.5% mol.), cuprous iodide (5.0 mg, 10% mol.), and trimethylsilylacetylene (178.0 µL, 1.25 mmol). Rapid purification by silica gel chromatography (cyclohexane:EtOAc; 100:0 to 50:50) yielded a grayish-white solid powder of alkyne 10 (100.0 mg, 85%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.60. 1 H NMR (acetone- d 6 (400MHz) δ 0.21 (s, 9H, H 20 ), 2.28 (s, 3H, H1), 7.08 (ddd, J = 8.0, J = 2.3, J = 1.1 Hz, 1H, H aro ), 7.26 (t, J = 7.9 Hz, 1H, H aro ), 7.38 (s, 1H, H4), 7.54 – 7.61 (m, 2H,H aro ), 7.62 (ddd, J = 7.8, J = 1.7, J = 1.0 Hz, 1H, H aro ), 7.75 – 7.82 (m, 2H, H aro ),7.86 (t, J = 1.9 Hz, 1H, H aro ), 9.10 (s, 1H, NH 磺酰胺 ), 11.14 (s, 1H, NH 乙酰基 ). 13 C NMR (acetone- d 6 (101 MHz): δ0.3 (3C), 22.8, 98.6, 104.0, 108.8, 119.60, 121.3, 123.1,128.2 (2C), 128.3, 130.3, 133.0, 136.7, 138.8, 140.5, 149.6, 159.0, 169.1.HRMS-ESI (m / z) [M+H] + C 22 H 24 Calculated value of N3O3S2Si: 470.10229; Measured value: 470.10260. HPLC (λ) 254 Purity 99.8%; t R : 10.71 min (Method 3).

[0134] N-(4-(3-((4-(dec-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB672). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (339.0 mg, 0.75 mmol), Pd(PPh3)4 (66.0 mg, 7.5% mol.), cuprous iodide (15.0 mg, 10% mol.), and dec-1-yne (677.0 µL, 3.75 mmol). Rapid purification by silica gel chromatography (petroleum ether: EtOAc; 100:0 to 50:50) yielded a grayish-white solid powder of alkyne 12 (323.5 mg, 85%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.65. 1 H NMR (acetone- d 6 , 400 MHz): δ 0.81 – 0.88(m, 3H, H 27 ), 1.23 – 1.32 (m, 8H, H aliph ), 1.41 (t, J = 7.3 Hz, 2H, H aliph ), 1.50–1.59 (m, 2H, H) aliph ), 2.28 (s, 3H, H1), 2.40 (t, J = 7.0 Hz, 2H, H 20 ), 7.09(ddd, J = 8.0, J = 2.2, J = 1.0 Hz, 1H, H aro ), 7.26 (t, J = 7.9 Hz, 1H, Haro ), 7.37 (s, 1H, H aro ), 7.45 – 7.53 (m, 2H, H aro ), 7.61 (dt, J = 7.8, J = 1.3 Hz, 1H, H aro ), 7.73–7.79 (m, 2H, H) aro ), 7.86 (t, J = 1.9 Hz, 1H, H aro ), 9.06 (s, 1H, NH 磺酰胺 ), 11.15(s, 1H, NH 乙酰基 ). 13 C NMR (acetone- d 6 (101 MHz): δ 14.3, 19.7, 22.8, 23.3, 29.2, 29.5,29.7, 29.8, 29.9, 32.5, 95.2, 108.8, 119.5, 121.2, 123.0, 128.1 (2C), 129.6,130.2, 132.6 (2C), 136.7, 138.9, 139.6, 149.6, 159.0, 169.1. HRMS-ESI (m / z) [M+H] + C 27 H 32 Calculated N3O3S2: 510.18796; Measured: 510.18829. HPLC (λ) 254 Purity: 97.2%; t R 10.42 min (Method 3).

[0135] N-(4-(3-((4-(4-(4-phenylbut-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB673). A general procedure for Sonogashira coupling was performed using bromoaryl 5a (339.0 mg, 0.75 mmol), Pd(PPh3)4 (66.0 mg, 7.5% mol.), cuprous iodide (15.0 mg, 10% mol.), and dec-1-yne (677.0 µL, 3.75 mmol). Rapid purification by silica gel chromatography (petroleum ether: EtOAc; 100:0 to 50:50) yielded a grayish-white solid powder of alkyne 13 (305.8 mg, 81%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.48. 1H NMR (400 MHz, acetone- d 6) δ 2.28(s, 3H, H1), 2.70 (t, J = 7.2 Hz, 2H, H 20 ), 2.87 (t, J = 7.4 Hz, 2H, H 21 ), 7.09(ddd, J = 8.1, J = 2.3, J = 1.0 Hz, 1H, H aro ), 7.19 (dq, J = 7.8, J = 2.8 Hz, 1H, H aro ), 7.22 – 7.33 (m, 5H, H aro ), 7.37 (s, 1H, H4), 7.40 – 7.49 (m, 2H, H aro ), 7.61(dt, J = 7.9, J = 1.3 Hz, 1H, H aro ), 7.72 – 7.78 (m, 2H, H aro ), 7.86 (t, J = 1.9 Hz, 1H, H aro ), 9.10 (s, 1H, NH 磺酰胺 ), 11.16 (s, 1H, NH 乙酰基 ). 13 C NMR (acetone- d 6 (101MHz): δ 22.0, 22.8, 35.5, 80.7, 94.5, 108.8, 119.5, 121.1, 123.0, 127.1, 128.1(2C), 129.1 (2C), 129.4, 129.4 (2C), 130.2, 132.6 (2C), 136.7, 138.9, 139.6,141.4, 149.6, 159.0, 169.1. HRMS-ESI (m / z) [M+H] + C 27 H 24 Calculated N3O3S2: 502.12536; Measured: 502.12558. HPLC (λ)254 Purity 99.8%; t R : 10.43 min (Method 3).

[0136] N-(4-(3-((3-(oct-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB617). A general procedure for Sonogashira coupling was performed using bromoaryl 6 (113.0 mg, 0.25 mmol), Pd(PPh3)4 (44.0 mg, 15% mol.), cuprous iodide (5.0 mg, 10% mol.), and oct-1-yne (185.0 µL, 1.25 mmol). Rapid silica gel chromatography (cyclohexane:EtOAc; 100:0 to 60:40) yielded a white-yellow powder of alkyne 14 (103.0 mg, 86%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.57. 1 H NMR (CDCl3, 200 MHz): δ 0.86 (t, J = 6.0 Hz, 3H,H 25 ), 1.41 – 1.20 (m, 6H, H 22 H 23 and H 24 ), 1.63 – 1.45 (m, 2H, H 21 ), 2.04 (s, 1H,H1), 2.33 (t, J = 6.9 Hz, 2H, H 20 ), 7.00 – 6.85 (m, 2H, H aro ), 7.12 (t, J = 8.0 Hz, 1H, H 10 ), 7.34 – 7.21 (m, 2H, H aro ), 7.50 – 7.39 (m, 3H, H aro) , 7.61 (d, J = 7.9Hz, 2H, H aro ), 7.83 (s, 1H, H aro ), 10.51 (s, 1H, NH 磺酰胺 ). 13 C NMR (CDCl3, 50 MHz): δ14.3, 19.6, 22.7, 23.2, 28.7, 28.8, 31.5, 79.1, 93.6, 108.9, 120.3, 121.7,123.5, 125.8, 126.0, 129.2, 129.9, 130.3, 135.7, 136.1, 136.9, 139.5, 148.7,159.0, 168.6. HRMS-ESI (m / z) [M+H] + C 25 H 28 Calculated value of N3O3S2: 482.1567; Measured value: 482.1574. HPLC (λ) 254 Purity: 98.9%; t R : 8.92 min (Method 1).

[0137] N-(4-(3-((3-(3-hydroxypropyl-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB619). A general procedure for Sonogashira coupling was performed using bromoaryl 6 (113.0 mg, 0.25 mmol), Pd(PPh3)4 (44.0 mg, 15% mol.), cuprous iodide (5.0 mg, 10% mol.), and propargyl alcohol (72.0 µL, 1.25 mmol). Rapid silica gel chromatography (cyclohexane:EtOAc; 100:0 to 60:40) yielded a white powdery alkyne 15 (76.1 mg, 71%) and unreacted starting material 6 (22.0 mg, 20%). Rf(EtOAc / cyclohexane, 2 / 1, v / v) = 0.38. 1 H NMR (CD3OD, 200 MHz): δ 2.21 (s, 3H, H1), 4.37 (s, 2H, H 20 ), 6.99 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H, H9), 7.29 – 7.17 (m, 2H, H4 and H 10 ), 7.41 (t, J = 7.8 Hz, 1H, H 16 ), 7.62 – 7.51 (m, 2H, H aro ), 7.71 (tt, J = 3.4, 1.5 Hz, 2H, H aro ), 7.80 (t, J = 1.8Hz, 1H, H aro ).13 C NMR (CD3OD, 50 MHz): δ 22.7, 51.2, 83.7, 91.2, 109.3, 120.1,121.7, 123.7, 125.5, 128.0, 130.4, 130.6, 131.0, 136.7, 137.2, 139.2, 141.6,150.4, 159.6, 171.1. HRMS-ESI (m / z) [M+H] + C 20 H 18 Calculated value of N3O4S2: 428.0733; Measured value: 428.0737. HPLC (λ) 254 Purity 97.5%; t R : 10.11 min (Method 3).

[0138] N-(4-(3-((3-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetyl amine (PB620). A general procedure for Sonogashira coupling was performed using bromoaryl 6 (113.0 mg, 0.25 mmol), Pd(PPh3)4 (44.0 mg, 15% mol.), cuprous iodide (5.0 mg, 10% mol.), and trimethylsilylacetylene (178.0 µL, 1.25 mmol). Rapid silica gel chromatography (cyclohexane:EtOAc; 100:0 to 50:50) yielded a pale yellow powder of alkyne 16 (98.2 mg, 84%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.52. 1 H NMR (CDCl3, 200 MHz): δ 0.17 (s, 9H, H 20 ), 1.94 (s, 3H, H1), 6.89 (d, J = 7.1 Hz, 2H, H aro ), 7.08 (t, J =7.8 Hz, 1H, H aro ), 7.46 – 7.17 (m, 3H, H aro ), 7.53 (d, J = 7.5 Hz, 1H, H aro ), 7.66(d, J = 8.0 Hz, 1H, H aro ), 7.90 (s, 1H, H aro), 8.18 (s, 1H, NH 磺酰胺 ), 10.97 (s, 1H,NH 乙酰基 ). 13 C NMR (CDCl3, 50 MHz): δ 0.1 (3C), 23.0, 97.5, 102.9, 109.0, 120.0,121.5, 123.4, 124.7, 126.9, 129.3, 129.9, 130.6, 135.6, 136.4, 136.9, 139.6,148.6, 159.4, 169.0. HRMS-ESI (m / z) [M+H] + C 22 H 24 Calculated value of N3O3S2Si: 470.1023; Measured value: 470.1033. HPLC (λ) 254 Purity: 96.6%; t R : 10.62 min (Method 3).

[0139] N-(4-(3-((3-ethynylphenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide (PB621). Solid K₂CO₃ (138 mg, 1.0 mmol) was added to a yellow methanol (4 mL) solution of alkyne 16 (51 mg, 0.108 mmol). The resulting suspension was stirred at room temperature for 14 hours. The mixture was partitioned between EtOAc and water, and the aqueous phase was extracted once with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. Rapid purification by silica gel chromatography (cyclohexane:EtOAc; 100:0 to 50:50) yielded a white powder of alkyne 17 (41.8 mg, 97%). Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.47. 1 H NMR (CD3OD, 200 MHz): δ 2.21 (s, 3H, H1), 3.64 (s, 1H, H 炔烃 ), 6.99 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H, H9), 7.33 – 7.16 (m, 2H, H4 and H 10 ), 7.42 (t, J = 7.8 Hz, 1H, H 16 ), 7.59 (ddt, J = 7.8, 3.5, 1.4 Hz, 2H, H aro), 7.73 (dt, J = 6.5, 1.6 Hz, 2H, H aro ), 7.85 (t, J = 1.7 Hz, 1H, H aro ). 13 C NMR (CD3OD, 50 MHz): δ 22.7, 81.1,82.7, 109.3, 120.2, 121.7, 123.7, 124.9, 128.4, 130.4, 130.6, 131.5, 137.2,137.2, 139.2, 141.6, 150.4, 159.6, 171.1. HRMS-ESI (m / z) [M+H] + C 19 H 16 Calculated value of N3O3S2: 398.0628; Measured value: 398.0626. HPLC (λ) 254 Purity: 96.9%; t R : 10.84 min (Method 3).

[0140] N-(3-(2-(methylamino)thiazo-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide (PB611). Sonogashira coupling was performed using 5b (325.0 mg, 0.77 mmol), Pd(PPh3)2Cl2 (80.6 mg, 15% mol.), cuprous iodide (21.9 mg, 15% mol.), and oct-1-yne (565.0 µL, 3.83 mmol). Rapid purification by silica gel chromatography (cyclohexane:EtOAc; 100:0 to 70:30) yielded a grayish-white powder, 21 (80.1 mg, 23%). 1 H NMR (acetone- d 6 (200MHz) δ 0.85 (t, J = 6.4 Hz, 3H, H 22 ), 1.70 – 1.18 (m, 8H, H 18 H 19 H 20 and H 21 ), 2.40(t, J = 6.8 Hz, 2H, H 17 ), 3.12 – 2.88 (m, 3H, H1), 6.73 (s, 1H, NH 噻唑), 6.87 (s,1H, H3), 7.11 (ddd, J = 8.0, 2.2, 1.2 Hz, 1H, H8), 7.23 (t, J = 7.8 Hz, 1H, H9),7.53 – 7.44 (m, 2H, H 13 ), 7.58 (dt, J = 7.7, 1.4 Hz, 1H, H 10 ), 7.91 – 7.70 (m, 3H, H6 and H) 12 ), 9.10 (s, 1H, NH 磺酰胺 ). 13 C NMR (acetone- d 6 (50 MHz) δ 14.4, 19.8, 23.2,29.2, 29.3, 31.8, 32.1, 80.2, 95.2, 102.0, 119.5, 120.6, 123.0, 128.2 (2C),129.6, 130.0, 132.7 (2C), 137.4, 138.8, 139.7, 151.4, 170.7. HRMS-ESI (m / z) [M+H] + C 24 H 28 Calculated value of N3O2S2: 454.1618; Measured value: 454.1615. HPLC (λ) 254 Purity: 96.6%; t R 12.03 mi (Method 3).

[0141] 4-(oct-1-yn-1-yl)-N-(3-(2-(phenylamino)thiazolyl-4-yl)phenyl)benzenesulfonamide (PB613). Sonogashira coupling was performed using 5c ​​(100.0 mg, 0.21 mmol), Pd(PPh3)2Cl2 (21.6 mg, 15% mol.), cuprous iodide (5.9 mg, 15% mol.), and oct-1-yne (151.7 µL, 1.03 mmol). Rapid purification by silica gel chromatography (cyclohexane:EtOAc; 100:0 to 70:30) yielded a brown powder, 22 (72 mg, 65%). 1 H NMR (acetone- d 6 (200 MHz) δ 0.86 (t, J = 6.2 Hz, 3H, H25 ), 1.67 – 1.11 (m, 8H, H 21 H 22 H 23 and H 24 ), 2.39 (t, J = 6.7 Hz, 2H, H 20 ), 7.01 (t, J = 7.3 Hz, 1H, H 12 ), 7.13 (d, J = 9.1 Hz, 2H, H6 and H 11 ), 7.33 (dt, J = 15.6, 7.8 Hz, 3H, H1 and H3), 7.48 (d, J = 8.2 Hz, 2H, H 16 ), 7.66(d, J = 7.7 Hz, 1H, H 13 ), 7.88 – 7.73 (m, 4H, H2 and H), 15 ), 7.92 (t, J = 1.9 Hz, 1H,H9), 9.14 (s, 1H, NH 噻唑 ), 9.35 (s, 1H, NH 磺酰胺 ). 13 C NMR (acetone- d 6 (50 MHz) δ 14.4,19.8, 23.2, 29.2, 29.3, 32.1, 80.2, 95.3, 103.8, 118.3 (2C), 119.5, 120.8,122.6, 123.0, 128.2 (2C), 129.7, 129.9 (2C), 130.3, 132.7 (2C), 137.0, 139.0,139.7, 142.4, 151.3, 164.5. HRMS-ESI (m / z) [M+H] + C 29 H 30 Calculated value of N3O2S2: 516.1774; Measured value: 516.1777. HPLC (λ) 280 Purity: 97.3%; t R : 11.96 min (Method 3).

[0142] N-(3-(2-aminothiazo-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide (PB622). The suspension of 1 was stirred at 80°C for 2 hours in 2M aq. HCl / EtOH (1 mL / 1 mL), followed by stirring at 50°C for 15 hours. The mixture was partitioned between EtOAc and saturated aq. Na2CO3, with the aqueous phase extracted once with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give pure amine 23 (20.8 mg, 99%) as a pale yellow solid. Rf(EtOAc / cyclohexane, 1 / 1, v / v) = 0.65. 1 H NMR (CD3OD, 200 MHz): δ 1.00 – 0.77 (m, 3H, H 21 ), 1.73 – 1.18 (m, 8H,H 17 H 18 H 19 and H 20 ), 2.39 (t, J = 6.8 Hz, 2H, H 16 ), 6.73 (s, 1H, H2), 7.08 – 6.92 (m, 1H, H8), 7.20 (t, J = 8.1 Hz, 1H, H8), 7.51 – 7.35 (m, 4H, H aro ), 7.76 – 7.62(m, 2H, H aro ). 13 C NMR (CD3OD, 50 MHz): δ 14.4, 20.0, 23.6, 29.6, 29.7, 32.5,90.3, 95.2, 103.5, 120.0, 121.4, 123.5, 128.2 (2C), 130.2, 130.3, 132.8 (2C),137.2, 139.1, 139.6, 150.9, 171.3. HRMS-ESI (m / z) [M+H] + C 23 H 26 Calculated value of N3O2S2: 440.1461; Measured value: 440.1472. HPLC (λ) 254 Purity 99.0%; t R : 8.89 min (Method 3).

[0143] Combination of Formula (I) compounds with different anticancer therapies Materials and Methods: Cell lines and reagents: Different cell lines were purchased from ATCC. Tumor cell lines were maintained at 37°C under a humidified atmosphere of 5% CO2 and cultured under normal growth conditions in DMEM, high glucose, GlutaMAX™ supplemented, and pyruvate-containing growth medium supplemented with 10% fetal bovine serum (ThermoFisher). Cells were treated with the indicated anticancer agents and / or BPR001-615 at the indicated concentrations and times. All drugs were dissolved in DMSO.

[0144] Proliferation analysis: Cell proliferation was measured using Abcam's WST-1 reagent (#ab65473). On day 0, cells were seeded in 96-well tissue culture plates. On day 1, cells were starved in serum (100 µL / well). On day 2, cells were treated with different drugs or DMSO at the indicated concentrations, in quadruplicates. 48 hours after treatment, WST-1 reagent (10 µL / well) was added. The plates were read at T0 at 450 nm on a Multiskan FC counter (ThermoScientific), and then read hourly until the OD reached 1.0. Cell proliferation is expressed as a percentage of absorbance after subtracting background (T0).

[0145] WST-1 assays were performed 48 hours after cells were treated with different concentrations of BPR001-615 and different concentrations of the indicated anticancer agent.

[0146] To evaluate the efficacy of BPR001-615 alone or in combination with another anticancer agent, we compared the observed and expected responses to the combination therapy. The Bliss model was used to predict the combined effects of each drug.

[0147] The expected combined effect (Eexp) is estimated based on the effect of each individual drug. "SE" corresponds to the significant efficacy of the combination of BPR001-615 with the identified anticancer agent.

[0148] Antibodies and reagents: Anti-HMGB1 antibody (#Ab18256), anti-Annexin A1 antibody (#Ab214486), and anti-Calreticulin antibody (#Ab2907) were purchased from Abcam (Paris, France). Anti-rabbit IgG and HRP-linked antibody (#7074S) were purchased from Cell Signaling (Paris, France). Secondary antibody: Texas Red goat antibody (#T6391) was purchased from ThermoFisher (Paris, France). Oxaliplatin (OXP, Cas 61825-94) and mitoxantrone (MTX, Cas 70476-82) were used to induce immunogenic cell death. The immobilizable active dye 510 (#564406) was purchased from BD Horizon (Paris, France).

[0149] HMGB1 release assay: A375 and CT26 cells were seeded at 180,000 cells / ml in 6-well plates containing 2% FBS. After 24 hours, the medium was changed and treatment was initiated. Oxaliplatin (OXP) was used at 50 µM and 100 µM, and BPR001-615 was used at 3 µM, 5 µM, and 7.5 µM. Forty-eight hours after treatment, the supernatant was collected, and dying tumor cells were removed by centrifugation. The supernatant was then immediately frozen at -20°C. Quantification of HMGB1 and Annexin A1 in the supernatant was assessed by loading 45 µL of the supernatant with loading buffer via Western blotting. Ponceau S-detectable BSA was used as a loading control.

[0150] For the ATP release assay, A375 and U2OS cells were seeded at 10,000 cells / ml in 96-well plates supplemented with 2% FBS. After 24 hours, treatment was added to the cells (50 µL / well) according to the manufacturer's instructions. Mitoxantrone (MTX) was used as a positive control at 5 µM, 10 µM, and 12.5 µM. BPR001-615 was used at doses ranging from 2.5 µM to 15 µM. After treatment, RealTime-Glo extracellular ATP assay reagent was added. The plates were mixed by orbital oscillation (300–500 rpm) for 30–45 seconds to ensure homogeneity. ATP release quantification was assessed using the RealTime-Glo extracellular ATP assay (Promega, #GA5010).

[0151] Flow cytometry was used to assess calreticulin expression. A375 cells were seeded at 180,000 cells / ml in 6-well plates of complete medium supplemented with 2% FBS. After 24 hours, the compound shown was added to the cells. BPR001-615 was used at the indicated concentration. We used flow cytometry to detect calreticulin, such as Liu... et al As described in Methods in Enzymology, 632:1-13, 2020.

[0152] result: BPR001-615 exhibits cytotoxic effects against cancer cell lines alone, accompanied by ICD properties, and responds in a dose-responsive manner. Issue 3 ICD marks: BPR001-615 is a BiP(GRP78) inhibitor that induces ER stress and CHOP-induced stress. Figure 1 A).

[0153] BPR001-615 triggers ER stress-induced and CHOP-mediated cancer cell death. Figure 1 B).

[0154] BPR001-615 triggers calreticulin exposure on the cell surface in various cancer cell lines. Figure 1 C).

[0155] BPR001-615 triggers the release of HMGB1 and AnnexinA1 ( Figure 2 A).

[0156] BPR001-615 triggers the release of extracellular ATP in various cancer cell lines. Figure 2 B).

[0157] These data generally indicate that BPR001-615 kills tumor cells through ER stress-induced apoptosis, autophagy, and ICD.

[0158] Compounds of formula (I), such as BPR001-615, combined with another anticancer therapy, can achieve synergistic anticancer effects: The results are summarized in the table below:

[0159] These results demonstrate that compounds of Formula I, such as BPR001-615, can significantly enhance the efficacy of anticancer therapies (including chemotherapy, targeted therapy, and immunotherapy) by triggering DAMP signaling through treatments that do not trigger or are insufficient to trigger ICD markers. They possess strong anticancer properties and target GRP78. The combination therapy provided a CHOP-mediated cytotoxic effect on cancer cells induced by endoplasmic reticulum (ER) stress, significantly exceeding the effects obtained by using each therapy alone.

[0160] The WST-1 cell proliferation assay was used to further investigate the combination therapy regimens of different concentrations of BPR001-615 with various chemotherapy drugs, 5-FU, oxaliplatin, docetaxel, or irinotecan metabolite SN38 in various gastric cancer cell lines. The effects of these combination therapies are summarized in Table 1:

[0161] Table 1 Summary of in vitro combined synergistic effects of BPR001-615 concentration with various chemotherapy regimens in gastric adenocarcinoma. All combined effects of chemotherapy dose-response are shown in... Figure 3 .

[0162] Treatment with BPR001-615 at 2, 2.5, and 5 µM in combination with chemotherapy has been shown to have a synergistic effect with chemotherapy in inducing cell death in GC cell lines (human). These results demonstrate the potential for improved treatment when standard-care chemotherapy is combined with BPR001-615.

[0163] To support this, GC cell line targeting and chemotherapy were combined in vivo in mice.

[0164] The combination of compound (I) and trastuzumab in the NCI-N87 model of humanized NXG mice grown in PBMC mice. Materials and Methods Forty 5-8 week old female NXG mice (Janvier Laboratories) were used in this study. Mice were allowed 7 days of acclimatization before entering the study. Animals were housed in IVC cages (maximum 5 mice per cage), with individual mice identified by tail tags. All animals had free access to standard certified commercial diet and sterilized water during the study. Standard conditions were maintained in the housing: 20-24°C, 45-65% humidity, and a 12-hour light / dark cycle. NCI-N87 cells (5 × 10⁻⁶) were introduced. 6 A 1:1 mixture of the drug and matrix gel was implanted into the back of female NXG mice. When the tumor reached approximately 150 mm... 3 Animals were randomly assigned to four treatment groups (7 animals per group): (i) solvent (15% Kolliphor HS15, 10% PEG400, 5% ethanol, 70% ultrapure water); (ii) BPR001-615 (150 mg / kg, orally twice daily (BiD) at 12-hour intervals); (iii) trastuzumab 10 mg / kg, intravenously (IV), on days 1 and 16; and (iv) a combination of BPR001-615 150 mg / kg and trastuzumab 10 mg / kg. PBMCs from the two donors were isolated, processed, and administered intravenously to the animals immediately before therapeutic dosing on the day of treatment to maximize the treatment window.

[0165] Tumors were measured three times a week using digital calipers. The length, width, and depth of the tumors were measured and used to calculate tumor volume. The weight of all mice in the study was also measured and recorded three times a week.

[0166] Due to observed efficacy, the tumors at the end of the group were excised and digested into a single-cell suspension, and then subjected to FACS analysis staining using the following antibody-immunoassay plates.

[0167] result BPR001-615 150 mg / kg BID, alone or in combination with trastuzumab, was well tolerated. BPR001-615, alone or in combination with trastuzumab, reduced intratumoral GRP78 concentrations, with a more significant reduction observed when the drugs were used in combination (see [link to relevant documentation]). Figure 4 ).

[0168] BPR001-615 150 mg / kg BID, alone or in combination with trastuzumab, resulted in a significant and similar reduction in NCI-N87 tumor growth in humanized PBMC animals (see [link to article]). Figure 5Compared with animals treated with trastuzumab, the combined treatment showed a better trend toward tumor volume reduction compared with animals treated with BPR001-615 alone.

[0169] FACS analysis of immune cell infiltration into tumor tissue at the end of the study indicated that BPR001-615 treatment produced a series of immune-mediated antitumor effects that may be involved in the observed efficacy and the synergistic effect of trastuzumab when used in combination. Compared with trastuzumab alone, CD3+ T cell and NK cell infiltration was significantly increased in the combination of BPR001-615 and trastuzumab, especially NK cells, while Treg infiltration was decreased. Figure 6 ).

[0170] BPR001-615, in combination with other therapies, induces tumor cell death. An overview of nonclinical in vitro and in vivo pharmacological studies of BPR001-615 in combination with chemotherapy and immune checkpoint inhibitors in colorectal cancer models is provided in Table 2.

[0171] Table 2. Overview of completed in vitro and in vivo pharmacological studies of BPR001-615 (or BPR001-615 in the table) in combination with chemotherapy and immune checkpoint inhibitors in colorectal cancer models. a-PD1: Anti-PD1; BID: Twice daily; IP: Intraperitoneal; N / A: Not applicable; PO: Oral; The solvent for BPR001-615 is 15% Kolliphor HS15, 10% PEG400, 5% EtOH, and 70% water, while the solvent for a-PD1 is PBS.

[0172] The combination therapy of BPR001-615 with the chemotherapy drugs SN38 and irinotecan metabolites in the CT26 cancer cell line was investigated using cell proliferation assays at different drug concentrations. The efficacy of this combination therapy was demonstrated... Figure 7 Treatment with 2.5 µM BPR001-615 in combination with chemotherapy has been shown to have a synergistic effect on inducing cell death in the CT26 cancer cell line. These results demonstrate the potential for improved treatment when standard-care chemotherapy is combined with BPR001-615.

[0173] This was further investigated in vivo using immune checkpoint inhibitors. The combination therapy of BPR001-615 with an anti-programmed cell death protein 1 antibody (a-PD1) was studied in C57BL / 6J female mice with subcutaneously implanted MC38 cancer cells. The study included four groups (n = 10 mice / group) to evaluate the effect of suboptimal oral administration of BPR001-615 combined with a-PD1 (intraperitoneal injection; IP) on overall survival. The efficacy of BPR001-615 combined with a-PD1 was primarily assessed by survival and tumor size evolution. In vivo evaluation results are shown in… Figure 8 Overall survival charts showed improvements in all treatment groups. Notably, the combination of BPR001-615 and α-PD1 (now a standard of care for many cancers, including gastric cancer) produced the most significant improvement, curing one more mouse compared to treatment alone. These results suggest that BPR001-615 may have a synergistic effect when used in combination with existing immunotherapies.

[0174] In vitro studies of another compound of formula (I) and compounds not covered by formula I To confirm the efficacy of compound I, further analyses were conducted in different cancer cell lines using the combination of BPR001-615 with cisplatin and irinotecan, as well as the combination of compound PB673 (N-(4-(3-((4-(4-phenylbut-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazolyl)acetamide) with cisplatin and irinotecan. Both BPR001-615 and PB673 showed synergistic effects with the two chemotherapy regimens. Figure 9 ).

[0175] The inventors also compared the efficacy of BPR001-615 in combination with HA15 in various chemotherapy regimens (cisplatin, docetaxel, irinotecan) in different cancer cell lines. When combined with each chemotherapy regimen, BPR001-615 showed superior efficacy compared to HA15, demonstrating that compounds of formula I are superior to other compounds when used in combination with anticancer agents. Figure 10 ).

[0176] In vivo efficacy of BPR001-615 against human NCI-N87 gastric tumors GC cell line NCI-N87 (1×10⁻⁶) was subcutaneously implanted. 7 The efficacy of BPR001-615 against gastric tumor growth was evaluated in Matrigel 1:1 PBMC humanized NXG female mice. When the tumor volume reached approximately 150 mm... 3At that time, PBMCs from two donors were isolated, processed, and administered IV to animals, followed by therapeutic dosing. BPR001-615 was administered orally at 150 mg / kg twice daily at 12-hour intervals until day 28. Studies were also conducted on seven mice treated with standard-of-care targeted therapy trastuzumab (a monoclonal antibody targeting HER2), administered on days 1 and 16.

[0177] During the administration period, good tolerability was observed, with no weight loss. Results showed that tumor growth in mice treated with BPR001-615 as a single agent was significantly inhibited, with a maximum tumor growth inhibition of up to 40%. Figure 11 Mice treated with BPR001-615 showed similar tumor growth inhibition as those treated with trastuzumab.

[0178] BPR001-615, when administered as a single dose, is as effective as trastuzumab as standard of care targeted therapy. This efficacy has been demonstrated in tumors with low BiP (or GRP78) expression, expanding the potential for patients to respond to treatment and thus resolving more than 50% of BiP-positive patients, which is significantly higher than the HER2-positive patient population targeted by trastuzumab (approximately 20%).

[0179] This discovery allows for the anticipated use of the compounds disclosed herein (as a monotherapy or in combination with an anticancer agent) for the treatment of all GRP78-overexpressing tumors, applicable not only to patients with high-GRP78 tumors but also to patients with low-GRP78 tumors, independent of HER2 status.

[0180] In this context, plasma GRP78 can also be used as a biomarker for patient selection based on plasma GRP78 expression (low or high).

Claims

1. Combination of anticancer therapy with compound (I): [Formula I]: in R1 represents H, methyl, phenyl, or acetyl; R2 represents H, or C2-C 10 Alkyl, cycloalkyl, or hydroxyalkyl; and The alkynyl chain connected to R2 is attached to the benzene ring at the 3 or 4 position. Its use in treating cancer in patients in need.

2. The combination for use according to claim 1, wherein the anticancer treatment is selected from chemotherapeutic agents, targeted therapies, and immunotherapeutic agents.

3. The combination for use according to claim 1 or 2, wherein the anticancer treatment is an immunotherapeutic agent selected from immune checkpoint inhibitors.

4. The combination for use according to claim 3, wherein the immune checkpoint inhibitor is an anti-PD-1 or anti-PDL1 antibody.

5. The combination for use according to any one of claims 1 to 4, wherein the compound of formula (I) is selected from the group consisting of: N-(4-(3-((4-(oct-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-(hex-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-(cyclohexylethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-ethynylphenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-(dec-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((4-(4-phenylbut-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((3-(oct-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((3-((trimethylsilyl)ethynyl)phenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(4-(3-((3-ethynylphenyl)sulfonylamino)phenyl)thiazo-2-yl)acetamide; N-(3-(2-(methylamino)thiazo-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide; 4-(oct-1-yn-1-yl)-N-(3-(2-(phenylamino)thiazolyl-4-yl)phenyl)benzenesulfonamide; as well as N-(3-(2-aminothiazo-4-yl)phenyl)-4-(oct-1-yn-1-yl)benzenesulfonamide.

6. The combination for use according to any one of claims 1 to 5, wherein the compound of formula (I) is BRP001-615 of formula (II): [Formula II]: 。 7. The combination for use according to any one of claims 1 to 6, wherein the cancer is selected from the group consisting of: breast cancer, bladder cancer, cervical cancer, colorectal cancer, pancreatic cancer, head and neck cancer, Hodgkin's lymphoma, liver cancer, lung cancer, kidney cancer, skin cancer, esophageal cancer, and stomach cancer.

8. The combination for use according to any one of claims 1 to 7, wherein the cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer.

9. The combination for use according to any one of claims 1 to 7, wherein the cancer is skin cancer, preferably melanoma.

10. The combination for use according to any one of claims 1 to 9, wherein the cancer is a non-immunogenic tumor.

11. The combination for use according to any one of claims 1 to 10, wherein the cancer is resistant to immunotherapy.

12. The combination for use according to claim 11, wherein the cancer is resistant to immune checkpoint inhibitors.

13. The combination for use according to any one of claims 1 to 12, wherein the patient has been identified as overexpressing GRP78.

14. The combination for use according to any one of claims 1 to 12, wherein the patient has a high GRP78 tumor or a low GRP78 tumor.

15. Reagent kit, including: - Anticancer agents; as well as - Compound of formula (I): [Formula I]: in R1 represents H, methyl, phenyl, or acetyl; R2 represents H, or C2-C 10 Alkyl, cycloalkyl, or hydroxyalkyl; and The alkynyl chain connected to R2 is attached to the benzene ring at the 3 or 4 position.

16. The kit according to claim 13, for use in treating cancer in patients in need.

Citation Information

Patent Citations

  • Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling

    US5811097A

  • Blockade of lymphocyte down-regulation associated with CTLA-4 signaling

    US5855887A

  • Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling

    US6051227A

  • Conjugate vaccine for nontypeable Haemophilus influenzae

    US6207157B1

  • Human monoclonal antibodies to CTLA-4

    US6682736B1